

A. Mark Fendrick
Professor, Department of Internal Medicine
North Campus Research Complex
2800 Plymouth Road
Building 16/418W
Ann Arbor, MI 48109
734-647-9688; amfen@umich.edu

Education

Sept 1974- Jun 1978 Scranton Central High School, Scranton, Pennsylvania

Sept 1978- May 1982 University of Pennsylvania (Economics/Chemistry), Philadelphia, Pennsylvania, B.A.

Sept 1982- May 1987 Harvard Medical School, Boston, Massachusetts, M.D.

Postdoctoral Training

Sept 1984- May 1985 Charles A. Dana Foundation Scholar, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania

Sept 1987- May 1990 Internship/Residency – Department of Internal Medicine, University of Pennsylvania Medical Center, Philadelphia, Pennsylvania

Sept 1991- May 1993 Robert Wood Johnson Foundation Clinical Scholar, University of Pennsylvania School of Medicine, Division of General Internal Medicine, Department of Medicine, University of Pennsylvania Medical Center and Philadelphia Veterans Affairs Medical Center

Certification and Licensure

1987-93 Pennsylvania (#042468-E)

1991- American Board of Internal Medicine (#1355160) Recertified 2015

1993- Michigan (#4301062417)

Academic Appointments

1985- Senior Fellow, Leonard Davis Institute of Health Economics, University of Pennsylvania, Philadelphia, Pennsylvania

1990 Associate, Swedish Council on Health Care Technology Assessment, Stockholm, Sweden

1991 Associate, Assistance Publique-Hospitaux de Paris, Ecole Polytechnique, Paris, France

1992-94	Lecturer, Department of Health Care Systems, Wharton School of Business, University of Pennsylvania, Philadelphia, Pennsylvania
1993-98	Assistant Professor, Division of General Medicine, Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, Michigan
1993-98	Assistant Professor, Department of Health Management and Policy, University of Michigan School of Public Health, Ann Arbor, Michigan
1996-2010	Co-Director, Consortium for Health Outcomes Innovation Cost Effectiveness Studies (CHOICES), Department of Internal Medicine, University of Michigan School of Medicine, Ann Arbor, Michigan
1998-2003	Associate Professor, Division of General Medicine, Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, Michigan
1998-2003	Associate Professor, Department of Health Management and Policy, University of Michigan School of Public Health, Ann Arbor, Michigan
1998-2016	Core Faculty, Robert Wood Johnson Clinical Scholars Program, University of Michigan, Ann Arbor, Michigan
2002-2010	Director, Health Services Research Core Laboratory, University of Michigan
2002-2004	Core Faculty, Society of General Internal Medicine - Hartford Foundation Collaborative Center for Research and Education in the Care of Older Adults
2003-	Professor, Division of General Medicine, Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, Michigan
2003-	Professor, Department of Health Management and Policy, University of Michigan School of Public Health, Ann Arbor, Michigan
2005-2012	Co-Director, Center for Value-Based Insurance Design, University of Michigan School of Public Health, Ann Arbor, Michigan
2012-	Director, Center for Value-Based Insurance Design, University of Michigan School of Public Health, Ann Arbor, Michigan

Scientific Activities

Editorships

2002-	Co-Editor in Chief, American Journal of Managed Care
2013-2019	Co-Editor in Chief, American Journal of Accountable Care

Editorial Board

1996-2002	Gastroenterology Therapy On-Line (http://www.gastrotherapy.com)
1997-2002	American Journal of Managed Care
1999-2008	Evidence-Based Gastroenterology
2002-2010	Clineguide
2004-2012	Medical Decision Making
2011-	CMDI Report
2011-	Integrated Pharmacy Research and Practice
2011-	Value-Based Oncology
2013-	Journal of Family Practice
2016-	Journal of Clinical Medicine

Grant Review

1996	Cost-Reducing Health Care Technologies, National Science Foundation
1998-1999	National Institute of Health, National Institute of Diabetes and Digestive and Kidney Diseases

2001	Medical Research Council (United Kingdom), Physiological Medicine and Infection Board
2005	Centers for Disease Control and Prevention (CDC), National Center for Chronic Disease Prevention and Health Promotion, Special Emphasis Panel
2014	Robert Wood Johnson Foundation, Changes in Health Care Financing and Organization (HCFO) Initiative
2020	Netherlands Organisation for Health Research and Development

Study Sections

2002-2008	National Institute of Health, Health Services Organization and Delivery
2006, 2012	National Institute of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Special Emphasis Panel

Grant Support

Current

PhRMA. Reducing Low-Value Care to Improve Affordability and Enhance Equity. Principal Investigator.
 ECOG-ACRIN/NIH/NCI. ECOP-ACRIN NCORP Research Base. Co-Investigator. Ruth Carlos, Principal Investigator.

Previous (since 2010)

InHealth. The Institute for Health Technology Studies. Value-Based Insurance Design for Diagnostics, Devices, and Procedures: A Novel Approach to Better Acknowledge Effectiveness and Value. Principal Investigator.
 Maine Health Management Coalition. Community Coalitions Health Institute Seed Grant Program. Value-Based Insurance Design for the Patient-Centered Medical Home. Consultant. Nancy Morris, Principal Investigator.
 National Institute of Health. Dizziness in the Emergency Department: A Population-Based Project. Mentor. Lewis Morgenstern, Principal Investigator.
 National Pharmaceutical Council (NPC). Value-Based Insurance Design for Specialty Pharmaceuticals: A Novel Approach to Better Acknowledge Effectiveness and Value. Principal Investigator.
 Gary & Mary West Health Policy Center, Inc. Expanding Coverage for Chronic Disease Care in High-Deductible Health Plans: Quality, Cost and Policy Implications. Principal Investigator.
 Robert Wood Johnson Foundation. State Health Access Reform Evaluation Program: The Clinical and Economic Impact of an Innovative “Clinically Nuanced” Benefit Design for Connecticut State Employees. Co-Investigator. Richard Hirth, Principal Investigator.
 Ohio Public Employees Retirement System. OPERS VBID Program Analysis. Co-Investigator. Rajesh Balkrishnan, Principal Investigator.
 PhRMA. The Role of Clinical Value in Formulary Development. Principal Investigator.
 Robert Wood Johnson Foundation. An Evaluation of Multi-Payer, Medical Episode-Based Payment Reform in Arkansas. Principal Investigator.
 National Pharmaceutical Council (NPC). Reward the Good Soldier: A Novel Approach to Benefit Design That Ties Consumer Cost-Sharing to Clinical Experience. Principal Investigator.
 AHRQ. Engaging Michigan Communities in Deliberations About Medicaid Priorities. Co-Investigator. Susan Goold, Principal Investigator.

State of New York, CMS. Role of V-BID in State of New York State Innovation Model. Principal Investigator.

Gary & Mary West Health Policy Center, Inc. Expanding Insurance Options for Chronic Disease Care: Quality, Cost and Policy Implications. Co-Investigator. Laurence McMahon, Principal Investigator.

Robert Wood Johnson Foundation. A National Survey of Value-Promoting Consumer Behaviors in High-Deductible Health Plans. Co-Investigator. Jeff Kullgren, Principal Investigator.

PhRMA. Analysis of Vaccine Cost-Sharing in the Medicare Program. Principal Investigator.

Global Health Living Foundation. The Role for Targeted Patient Assistance Programs to Enhance Access to Clinically-Indicated Medications in the Setting of Increased Cost-Related Non-adherence. Principal Investigator.

California Public Employees Retirement System (CalPERS). Incorporating Value-Based Insurance Design in the California Public Employees Retirement System. Principal Investigator.

PhRMA. Indication-Specific Pricing Coupled with Value-Based Insurance Design: Opportunities to Drive More Health per Pharmacy Dollar. Principal Investigator.

Laura and John Arnold Foundation. Quantitative Evaluation of Arkansas Episodic Payment Initiative. Principal Investigator.

PhRMA. Estimating the Value of Pharmaceuticals in Common Chronic Conditions in Medicare Beneficiaries. Principal Investigator.

State of Michigan, CMS. Healthy Michigan Plan CMS Evaluation FY17. Co-Investigator. John Ayanian, Principal Investigator.

AHRQ. Impact of No Cost Contraception on Utilization and Direct Medical Expenditures. Co-Investigator. Vanessa Dalton, Principal Investigator.

Laura and John Arnold Foundation. Designing a High-Value Health Plan. Michael Chernen, Principal Investigator.

Boehringer Ingelheim. Outcomes-Based Contracting with Value-Based Insurance Design: Opportunities to Drive More Health Per Pharmacy Dollar. Principal Investigator.

PhRMA. An Estimation of the Health and Economic Impact of Pharmaceuticals in Medicare Beneficiaries with Chronic Conditions. Principal Investigator.

PhRMA. Engaging State Stakeholders to Identify and Remove Low-Value Care. Principal Investigator.

Honors and Awards

1978	Pennsylvania State Senatorial Scholar
1980	Alpha Epsilon Delta Honor Society
1982	Summa cum laude, University of Pennsylvania
1992, 1993	American Federation for Clinical Research Trainee Award
1994-1996	Career Development Award in Pharmacoeconomics and Outcomes Research, Pharmaceutical Research and Manufacturers of America Foundation
1996	Governor's Award, American College of Gastroenterology
1997	Best Poster Prize, 13 th Annual Meeting of the International Society for Technology Assessment in Health Care, Barcelona, Spain
2001	Best Podium Presentation, 4 th Annual European Congress, International Society for Pharmacoeconomics and Outcomes Research, Cannes, France
2004-2006	Society of General Internal Medicine, Research Mentorship Award (with Peter Cram, MD, MBA)

2009	Health Care Research Award, National Institute for Health Care Management Foundation
2011	Testimony, United States Senate, Committee on Health, Education, Labor, & Pensions
2013	Testimony, United States House of Representatives, Ways & Means Subcommittee on Health
2013	Token of Appreciation from Medical Students Award, UM Medical School
2014	Testimony, State of Michigan Health Policy Committee
2014	Molly and Sidney N. Zubrow Award, Pennsylvania Hospital, Penn Medicine
2014	Elected to the Institute of Medicine National Academy of Sciences
2015	Kauver Lectureship, University of Colorado Denver
2016	Testimony, State of Michigan Senate HHS Subcommittee
2016	Testimony, United States Senate, Armed Services Personnel Subcommittee
2017	Testimony, United States House of Representatives, Ways & Means Subcommittee on Health
2017	Policy Award, National Forum for Heart Disease & Stroke Prevention
2019	W. Allen Tisdale Lecture, University of Vermont Larner College of Medicine
2021	Testimony, State of Massachusetts Joint Committee on Health Care Financing

Memberships and Offices in Professional Societies

1993-	Member, American College of Physicians
1993-2001	International Society for Technology Assessment in Health Care, Board of Directors, 1995-1998
1993-	Member, Society of General Internal Medicine
1993-2010	Member, Society for Medical Decision Making
1996-2010	International Society for Pharmacoeconomics and Outcomes Research, Board of Directors, 2000-2002

Teaching Activities

National

1991-1993	Lecturer, The Health Care System, Wharton School of Business, University of Pennsylvania, Philadelphia, PA.
Mar 2019	Value-Based Insurance Design. Fuqua School of Business, Duke University, Durham, NC.

University of Michigan (selected since 2010)

Feb 2010	Value-Based Insurance Design: More Health at Any Price. Grand Rounds, Department of Internal Medicine.
Feb 2010	Economic Analysis and Value-Base Insurance Design. Clinical and Translational Research. BIOS 557, School of Public Health.
Apr 2010	Value-Based Insurance Design. Robert Wood Johnson Clinical Scholars Program.
Apr 2010	Value-Based Insurance Design. College of Pharmacy.
Aug 2010	Economic Evaluation and Decision Analysis. Robert Wood Johnson Clinical Scholars Program Summer Session.
Sept 2010	Value-Based Insurance Design. IOE 691, School of Engineering.

Feb 2011 Value-Based Insurance Design. HMP 631, School of Public Health.

Apr 2011 Value-Based Insurance Design. Robert Wood Johnson Clinical Scholars Program.

Aug 2011 Economic Evaluation and Decision Analysis. Robert Wood Johnson Clinical Scholars Program Summer Session.

Oct 2011 Value-Based Insurance Design. M2 Health Economics/Health Policy Core Lecture, School of Medicine.

Oct 2011 Value-Based Insurance Design. HSPA Presentation, School of Public Health.

Nov 2011 Value-Based Insurance Design. HMP Workshop for Integrating and Discussing Topics in Healthcare, School of Public Health.

Nov 2011 V-BID Center Symposium.

Nov 2011 Value-Based Insurance Design. Alpha Epsilon Delta.

Dec 2011 Value-Based Insurance Design. IOE 691, School of Engineering.

Dec 2011 Value-Based Insurance Design. Department of Obstetrics and Gynecology HSR Seminar.

Feb 2012 Value-Based Insurance Design. Noon Conference, Department of Internal Medicine.

Feb 2012 Value-Based Insurance Design. UC280, Undergraduate Research Opportunity Program Biomedical Seminar.

Aug 2012 Economic Evaluation and Decision Analysis. Robert Wood Johnson Clinical Scholars Program Summer Session.

Feb 2013 Value-Based Insurance Design. Noon Conference, Department of Internal Medicine.

Apr 2013 Preparing Testimony for Policymakers. HMP 617, School of Public Health.

May 2013 "Point-Counterpoint: Should Researchers Be Advocates?" Institute for Health Policy & Innovation Seminar Series.

Aug 2013 Economic Evaluation and Decision Analysis. Robert Wood Johnson Clinical Scholars Program Summer Session.

Sept 2013 Value-Based Insurance Design: Translating Research to Policy. Robert Wood Johnson Clinical Scholars Program.

Oct 2013 Value-Based Insurance Design: Translating Research into Policy. Department of Radiology. Grand Rounds.

Feb 2014 Women's Reproductive Health and the Affordable Care Act. WS 400.

Mar 2014 Pharmacoeconomics and Outcomes Research. HMP 637, School of Public Health.

Mar 2014 Evidence-Based Medicine: Ethics. P 545, College of Pharmacy.

Mar 2014 Health Insurance and Payment. HMP 631, School of Public Health.

Aug 2014 Economic Evaluation and Decision Analysis. Robert Wood Johnson Clinical Scholars Program Summer Session.

Nov 2014 Cost-effectiveness Analysis in Health. HMP 610, School of Public Health.

Jan 2015 Value-Based Insurance Design. Robert Wood Johnson Clinical Scholars Program. Noon Conference.

Feb 2015 How Obamacare Makes Preventive Care Easier for Consumers: Educational Discussions for Clinical Nurses. University of Michigan Taubman Clinic.

Feb 2015 Internal Medicine Noon Conference.

Mar 2015 Health Economics II. HMP 663, School of Public Health.

Sept 2015 Strategies to Build Policy Impact in an Interdisciplinary Cancer Care Delivery Program. CanSORT Annual Meeting.

Oct 2015 General Medicine Research Conference.

Nov 2015 Cost Effectiveness Analysis. HMP 610, School of Public Health.
 Dec 2015 Pharmacoeconomics & Outcomes Research. HMP 637, School of Public Health.
 Dec 2015 University Health Services CME Lecture.
 Dec 2015 UMHS IT Update Session.
 Dec 2015 Hematology/Oncology Journal Club. Value Initiatives in Cancer Care.
 Jan 2016 Internal Medicine Noon Conference.
 Feb 2016 Understanding & Improving the US Healthcare System MOOC.
 Mar 2016 Medical Benefit Advisory Committee.
 Jun 2016 Hematology/Oncology Research Conference.
 Jun 2016 IHPI Lunch & Learn.
 Jul 2016 National Scholars Summer Session.
 Nov 2016 Cost Effectiveness Analysis. HMP 610, School of Public Health.
 Nov 2016 General Medicine Research Conference.
 Jan 2017 Alpha Epsilon Delta.
 Jan 2017 Case Studies in Health Services Administration. HMP 682, School of Public Health.

 Feb 2017 Understanding & Improving the U.S. Healthcare System MOOC.
 Mar 2017 UMHS Healthcare Administration Scholars Program.
 Jul 2017 National Scholars Summer Session.
 Nov 2017 Cost-Effectiveness Analysis. HMP 610, School of Public Health.
 Feb 2018 Dean's Scholars Program.
 Feb 2018 UMHS Healthcare Administration Scholars Program.
 Mar 2018 Michigan Center for Inter-Professional Education.
 Jun 2018 Michigan Medical Scholars. Multi-Disciplinary Symposium.
 Jul 2018 National Clinician Scholars Program.
 Sept 2018 Health Services Research Symposium.
 Nov 2018 National Clinician Scholars Program. Noon Seminar.
 Apr 2019 UMHS Healthcare Administration Scholars Program.
 Jun 2019 Health Policy and Health Economics Path of Excellence. Seminar.
 Jul 2019 National Clinical Scholars Program.
 Oct 2019 Cost-Effectiveness Analysis. HMP 610, School of Public Health.
 Nov 2019 Reimbursement Strategies, Value & Quality. Ford School of Public Policy.
 Dec 2019 Center for Healthcare Outcomes & Policy (CHOP). Department of Surgery.
 Jan 2020 UMHS Healthcare Administration Scholars Program.
 Feb 2020 UMMS. Strategic Management for Physicians. Introducing the Professional Physician.

 Feb 2020 Internal Medicine Noon Conference.
 Mar 2020 Economics of Health Management and Policy. HMP 660, School of Public Health.

 Apr 2020 V-BID: Enhancing Access and Affordability to Essential Clinical Services During COVID-19 and Beyond. Grand Rounds, Department of Internal Medicine.

 July 2020 IHPI/NCSP Summer Sessions: Measuring & Rewarding Value; The Rise of High-Deductible Plans.

 Oct 2020 2020 Presidential Platforms in Healthy Policy, Health Policy Path of Excellence.
 Oct 2020 Cost-Effectiveness Analysis. HMP 610, School of Public Health.
 Nov 2020 Economics of Health Management and Policy. HMP 660, School of Public Health.

Jan 2021 Value-Based Cases. Patients & Populations Branch.
 Jan 2021 UMHS Healthcare Administration Scholars Program.
 Mar 2021 Risk and Insurance. HMP 631, School of Public Health.
 July 2021 IHPI/NCSP Summer Sessions: Turning a Crisis Into Opportunity: Can COVID-19 Help Set a Path to Improved Health Care Efficiency?

Committee and Administrative Services (since 2002)

National (since 2002)

2002 Expert Reviewer, Management of Chronic Hepatitis C, AHRQ Publication 02-E030, Agency for Healthcare Research and Quality
 2003-2006 Medical Advisory Board, Pri-Med Institute
 2003-2008 Cost-effectiveness Subcommittee, Chronic Renal Insufficiency Cohort Study (CRIC), National Institutes of Health
 2004- Centers for Medicare and Medicaid Services, Medicare Coverage Advisory Committee (MEDCAC)
 2004-2011 Pharmacy and Therapeutics Committee, MedImpact Healthcare Systems, Inc.
 2005-2012 Scientific Advisory Committee, Institute for Health Technology Studies (InHealth)
 2005-2012 Scientific Advisory Committee, K30 Mentored Training Program in Clinical Investigation, Washington University School of Medicine
 2007-2011 Advisory Committee, Pfizer Scholars Program in Health Policy
 2009-2013 Advisory Board, Center for Medical Technology Policy
 2010-2012 Advisory Committee, Community Coalitions Health Institute (CCHI), National Business Coalition on Health
 2011- External Advisory Committee, Section for Value and Comparative Effectiveness, New York University School of Medicine
 2011-2013 Committee on Geographic Variation in Health Care Spending and Promotion of High-Value Care, IOM, NAS
 2011- Advisory Council, North Carolina Prevention Partners
 2012- Advisory Board, Virginia Center for Health Innovation
 2012-2016 Advisory Board, Health Care Incentives Improvement Institute
 2012-2016 Co-Chair, Employer-Purchaser Engagement Center, Patient-Centered Primary Care Collaborative
 2014-2016 Advisory Board, IMS Health
 2014- Advisory Board, Catalyst for Payment Reform
 2014-2016 Executive Steering Committee, Fit for Work America
 2015 Advisory Board, Patient-Centered Outcomes Research Institute (PCORI)
 2015- Selection Committee, Hearst Health Prize for Excellence in Population Health
 2016- Member, AcademyHealth - ABIM Foundation Community on Low-Value Care
 2016- Advisory Board, International Society for Pharmacoeconomics and Outcomes Research Initiative on Value Assessment Frameworks
 2016- Advisory Board, Springboard Healthy Scranton, Geisinger Health System
 2020- Co-Chair, Workshop: Why Has the Progress on Hypertension Control Ceased in the U.S. and How Can Progress Be Restarted: NIH's Role? NHLBI CDC

Michigan

2008-2013 Co-Chair, Michigan Cardiovascular Alliance, Michigan Department of Community Health

University of Michigan

2000-2005 New Medical Technology Assessment Committee, M-Care
2002-2005 Chair, Collaborative Health Services Research Initiative for Practice Improvements, University of Michigan Health System
2002-2010 Awards Committee, Department of Internal Medicine
2002 Executive Committee, Center for the Advancement of Clinical Research
2002 Grant Reviewer, Life Sciences, Values and Society Program
2003 Advisory Committee, K30 Clinical Research Training Program
2005-2008 Co-chair, Value-Based Benefit Committee, Michigan Healthy Community Initiative
2006- Scientific Advisory Committee, Faculty Research Development Program, Department of Radiology
2013 Participant, 14th Annual Michigan Road Scholars Tour
2015-2016 Member, President's Committee on National Service & Policy Engagement

Consulting Positions

1993- Merck and Co.
2010- Zansors
2013- Amgen
2013- Center for Medicare and Medicaid Services (CMS)
2013-2018 Lilly
2014-2016 Pfizer
2014-2016 Sanofi
2015- Sempre Health
2015- Wellth
2016- AbbVie
2016- Freedman Health
2017- MedZed
2017- Risalto Health
2017-2018 Takeda
2017- Centivo
2017- State of Minnesota
2017- Bayer
2017- Exact Sciences
2018- Community Oncology Association
2018- Health at Scale Technologies
2018-2019 Intarcia
2018- EmblemHealth
2018- PenguinPay
2018-2019 Health Management Associates
2019- Virginia Center for Health Innovation
2019- U.S. Department of Defense
2019- Health & Wellness Innovations
2019- GRAIL, Inc.

2019-	Covered California
2019-	Yale – New Haven Health System
2019-	Montana Health Cooperative
2020-	HealthCorum
2020-	Phathom Pharmaceuticals, Inc.
2020-	Risk International
2020-	Hygieia
2020-	Wildflower Health
2021-	Pair Team
2021-	Mercer
2021-	MedIncontext
2021-	Silver Fern Healthcare

Visiting Professorships

Feb 1998	Oregon Health Sciences University
Feb 1998	University of Connecticut Health Science Center
Oct 1998	University of New Mexico School of Medicine
Nov 1998	McMaster University
Jun 2000	Medical College of Wisconsin
Mar 2002	University of California at Los Angeles
Feb 2003	Temple University
Sept 2003	Oklahoma University Health Sciences Center
Aug 2004	University of Iowa
Oct 2004	University of Manitoba Faculty of Medicine
Mar 2005	UMDNJ-Robert Wood Johnson Medical School
Apr 2005	Cleveland Clinic Foundation
Apr 2007	University of Illinois at Chicago
Mar 2011	University of Pennsylvania
Feb 2012	University of Chicago
Apr 2015	University of Colorado
Oct 2015	Yale University
Apr 2016	Memorial Sloan Kettering
Jul 2016	Stanford University
Apr 2017	Harvard Medical School
Oct 2019	University of Vermont Larner College of Medicine

Extramural Invited Presentations

International (selected since 2015)

“Value Based Insurance Design”

Chinese Economic Society. Shenzhen, China. Jun 2016.

China-U.S. Precision Medicine Industry & Policy Forum. Shenzhen, China. Jun 2016.

Beijing Hospital. Beijing, China. Jun 2016.

Transformative Primary Care: Promoting Health and Well-Being for Displaced, Immigrant, and Vulnerable Patients. Rome, Italy. Sept 2019.

The 2nd Sichuan Health and Insurance Forum Agenda. Web presentation. Oct 2020.

National (selected since 2015)

“Value Based Insurance Design.”

Families USA Health Action Conference. Washington, DC. Jan 2015.
Evergreen Health. Baltimore, MD. Jan 2015.
Worldwide Employee Benefits, Cleveland Chapter. Cleveland, OH. Feb 2015.
Worldwide Employee Benefits. Webinar. Feb 2015.
Journal of the American College of Radiology. Tweet Chat. Feb 2015.
Integrated Benefits Institute (IBI). San Francisco, CA. Mar 2015.
OmedaRx EBM Assessments & Adherence Conference. San Francisco, CA. Mar 2015.
U.S. Chamber of Commerce. Washington, DC. Apr 2015.
Jefferson School of Population Health. Health Forum. Philadelphia, PA. Apr 2015.
International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 20th Annual International Meeting. Philadelphia, PA. May 2015.
National Association of Health Underwriters Education Foundation. Webinar. May 2015.
National Academy of Social Insurance Medicare at 50. Washington, DC. Jun 2015.
New York State Innovation Model Webinar. Albany, NY. Jun 2015.
National Governors Association, National Academy of Medicine. Harrisburg, PA. Jul 2015.
AJMC. Tweet Chat. Jul 2015.
Smarter Health Care Coalition Congressional Briefing. Washington, DC. Jul 2015.
The Colorado Health Foundation 2015 Health Symposium. Keystone, CO. Jul 2015.
State Health Access Reform Evaluation (SHARE). Webinar. Aug 2015.
CMMI State Innovation Model Grantees. Webinar. Aug 2015.
Academy of Managed Care Pharmacy. Washington, DC. Sept 2015.
Yale University, Dept of Int Medicine Grand Rounds. New Haven, CT. Sept 2015.
American Federation of Teachers. AFL-CIO. Webinar. Sept 2015.
Alliance for Health Reform Roundtable. Washington, DC. Sept 2015.
HFMA’s 9th Annual Thought Leadership Retreat. Washington, DC. Oct 2015.
Florida Hospital Association Managed Care Conference. Orlando, FL. Oct 2015.
Houston Business Coalition on Health. Houston, TX. Nov 2015.
Public Sector Health Care Roundtable. Washington, DC. Nov 2015.
Consumers Union. Health Care Costs & Quality. New Orleans, LA. Nov 2015.
American Federation of Teachers. AFL-CIO. Webinar. Dec 2015.
National Diabetes Prevention Program Summit. Baltimore, MD. Dec 2015.
Pennsylvania Department of Health. Harrisburg, PA. Dec 2015.
Virginia Center for Health Innovation. Richmond, VA. Jan 2016.
Connecticut V-BID Consortium. Webinar. Jan 2016.
Evolent Health Employer Provider Summit. Nashville, TN. Jan 2016.
Pennsylvania SIM Alternative Payment Work Group. Webinar. Jan 2016.
Baycare Biannual Employer Symposium. Tampa, FL. Feb 2016.
National Association of State Health CO-OPs. Washington, DC. Feb 2016.
PAN Foundation Cost-sharing Roundtable. Washington, DC. Feb 2016.
Health Affairs. Patients’ and Consumers’ Use of Evidence. Washington, DC. Apr 2016.
Virginia Hospital and Healthcare Association. Webinar. Apr 2016.
California Association of Health Plans (CAHP). San Francisco, CA. Apr 2016.
Geisinger Health System Speaker Series. Danville, PA. Apr 2016.
SALGBA 2016 Conference. San Antonio, TX. Apr 2016.
Army-Baylor University Graduate Program in Health and Business Administration.
San Antonio, TX. Apr 2016.

Center for Health Policy and Outcomes Seminar. Memorial Sloan Kettering. New York, NY. Apr 2016.

City of New York, Department of Health & Mental Hygiene. New York, NY. Apr 2016.

U.S. Department of Defense. Military Health Agency. Falls Church, VA. May 2016.

Oklahoma Center for Healthcare Improvement. Tulsa, OK. May 2016.

OPERS Health Care Horizons Forum. Columbus, OH. Jun 2016.

Stanford University, Dept of Int Medicine Grand Rounds. Palo Alto, CA. Jul 2016.

California Public Employees' Retirement System. Board of Directors. Sonoma, CA. Jul 2016.

Merck & Co., Inc., Grand Rounds. Gwynedd, PA. Sept 2016.

3M Value-Based Care Conference. Chicago, IL. Sept 2016.

ACOEM/NBGH Health & Productivity. Webinar Series. Sept 2016.

ACOs & Emerging Healthcare Delivery Coalition. Philadelphia, PA. Oct 2016.

Healthcare Vision Summit. Washington, DC. Nov 2016.

MedInsight Client Forum. San Diego, CA. Nov 2016.

J & J Healthcare Systems Meeting. Dallas, TX. Nov 2016.

Pacific Business Group on Health. San Francisco, CA. Dec 2016.

Milliman Healthcare Intelligence Client Forum. Webinar. Jan 2017.

Journal of the American College of Radiology. Tweet Chat. Jan 2017.

AAPAN Annual Forum. Tucson, AZ. Jan 2017.

AcademyHealth National Health Policy Conference. Washington, DC. Jan 2017.

NPC Board of Directors Meeting. Washington, DC. Feb 2017.

Patient Assistance Network Cost-Sharing Roundtable. Washington, DC. Feb 2017.

National Academy of Medicine Roundtable on Genomics & Precision Health. Washington, DC. Mar 2017.

WELLCOM Health. Wealth, and Work Benefits Series. Omaha, NE. Apr 2017.

Health Plan Alliance. Spring Leadership Meeting. Southlake, TX. Apr 2017.

Better Medicare Alliance National Medicare Advantage Summit. Arlington, VA. Apr 2017.

Pharmaceutical Policy Research Seminar. Department of Population Medicine. Harvard Medical School, Harvard University, Boston, MA. Apr 2017.

SALGBA 2017 National Conference. Orange County, CA. May 2017.

Healthcare Career Advancement Program. Chicago, IL. Jun 2017.

Employee Benefit Research Institute Policy Forum #81. Washington, DC. Jul 2017.

BIO. Congressional Briefing, "The Cost and Value of Prescription Medicines". Washington, DC. Jul 2017.

National Forum for Heart Disease and Stroke Prevention Value and Access Steering Committee Focus on Value-Based Insurance Design. Webinar. Jul 2017.

National Pharmaceutical Council. "Same Condition, Different Costs: Should Patients Pay Different Amounts?" Webinar. Jul 2017.

Alliance for Health Policy Summit. Washington, DC. Jul 2017.

Centers for Medicare & Medicaid Services. Center for Consumer Information and Insurance Oversight Speaker Series. Bethesda, MD. Sept 2017.

Center for Medicine in the Public Interest. Washington, DC. Sept 2017.

BenefitFocus Carrier Executive Forum. Charleston, SC. Sept 2017.

Accenture Value Based Care Delivery Community Call. Webinar. Sept 2017.

Silicon Valley Employers Forum Roundtable. Sunnyvale, CA. Oct 2017.

Community Oncology Alliance Payer Exchange Summit VII. Tysons, VA. Oct 2017.

Smarter Health Care Coalition Summit. Washington, DC. Oct 2017.

Takeda-Lundbeck Annual Partner Day. Washington, DC. Nov 2017.

Provider Network Symposium. West Hartford, CT. Dec 2017.

NBGH. An Employer's First Steps Toward Paying for Value. Webinar. Dec 2017.

AMA Council on Medical Service Policy Makers. Washington, DC. Jan 2018.

AHIP Employer Sponsored Insurance: Attitudes and Innovation. Washington, DC. Feb 2018.

Rhode Island Business Group on Health Legislative Breakfast. Providence, RI. Feb 2018.

American Hospital Association Provider-Sponsored Health Plan Strategic Leadership Group Meeting. Chicago, IL. Apr 2018.

2018 Community Oncology Alliance Conference. Washington, MD. Apr 2018.

Freedman Healthcare. Connecticut V-BID Technical Assistance I. Webinar. May 2018.

Midwest Business Group on Health. Chicago IL. May 2018.

Pittsburgh Business Group on Health Rx Solutions Forum. Pittsburgh, PA. May 2018.

Better Medicare Alliance National Medicare Advantage Summit. Washington, DC. May 2018.

Atlantic State of Care. Washington, DC. May 2018.

Freedman Healthcare. Connecticut V-BID Technical Assistance II. Webinar. May 2018.

American Medical Association Annual Meeting. Chicago, IL. Jun 2018.

NEBGH 7th Annual Health & Wellness Benefits Conference. New York, NY. Jun 2018.

Freedman Healthcare. State Innovation Model Value Based Insurance Design Consortium. Webinar. Jun 2018.

Freedman Healthcare. Connecticut V-BID Technical Assistance III. Webinar. Jun 2018.

American Diabetes Association's 78th Scientific Sessions. Orlando, FL. Jun 2018.

Health Plan Alliance Health System and Health Plan Leadership Forum. Chicago, IL. Jun 2018.

Institute for Healthcare Policy and Innovation. Vail Symposium. Vail, CO. Jul 2018.

National Forum. Value and Access Partner Spotlight. Webinar. Aug 2018.

America's Physician Groups Member. Webinar. Aug 2018.

Employee Benefit News. Benefits Forum and Expo 2018. New Orleans, LA. Sept 2018.

The Alliance Northwest Employer Meeting. Eau Claire, WI. Sept 2018.

ASCO Oncology Practice Conference. Phoenix, AZ. Sept 2018.

Center for Workforce Health and Performance. V-BID in Action: The Case of Diabetes. Webinar. Oct 2018.

NORD Rare Diseases and Orphan Products Breakthrough Summit. Washington, DC. Oct 2018.

Health Care Payment Learning & Action Network. LAN Fall Summit. Tysons, VA. Oct 2018.

Smarter Health Care Coalition Fall Summit. Washington, DC. Oct 2018.

Association for Value-Based Cancer Care Summit. New York, NY. Oct 2018.

St. Louis Area Business Health Coalition Annual Meeting. St. Louis, MO. Oct 2018.

Association of Black Cardiologists. Dr. Walter M. Booker, Sr. Memorial Symposium. Chicago, IL. Nov 2018.

Connecticut Joint Replacement Institute, Connecticut Health Council, Connecticut Business Group on Health. Moving to Value Forum. Hartford, CT. Dec 2018.

UCLA Health. Natural Experiments in Translation for Diabetes. Bethesda, MD. Jan 2019.

Health Care Transformation Task Force. Consumer Engagement in Benefit Design. Webinar. Feb 2019.

American Medical Student Association. Health Care for All Scholars Program. Webinar. Feb 2019.

National Pharmaceutical Council. Going Below the Surface Forum. Washington, DC. Feb 2019.

VBID Health. Low-Value Care 101 Webinar. Webinar. Feb 2019.

Fuqua School of Business, Duke University. Durham, NC. Mar 2019.

Relph Benefit Advisors. 20/20 Vision Conference. Verona, NY. Mar 2019.

HealthCare 21 Business Coalition Health & Productivity Forum. Knoxville, TN. May 2019.

Alliance of Community Health Plans Spring 2019 Clinical Meeting. Dallas, TX. May 2019.
 The Hill. Cost, Quality and Care: The Medicare Equation. Washington, DC. Jun 2019.
 Public Sector HealthCare Roundtable. 2nd Annual Congressional Forum. Washington, DC.
 Jun 2019.
 Better Medicare Alliance Medicare Advantage Summit. Washington, DC. Jul 2019.
 V-BID X: A New Plan Option for the Individual Health Insurance Market Webinar.
 Ann Arbor, MI. Jul 2019.
 Smarter Care Virginia. VA Center for Health Innovation. Richmond, VA. Aug 2019.
 Centers for Disease Control & Prevention. Hypertension Control Planning Meeting.
 Atlanta, GA. Sept 2019.
 Congressional Black Caucus Foundation, Inc. Annual Legislative Conference.
 Washington, DC. Sept 2019.
 American Heart Association. CEO Roundtable. Sept 2019.
 Harvard University. 9th U.S.-China Health Summit. Boston, MA. Sept 2019.
 National Alliance Annual Forum. Benefit Design in Action: Eliminating Low-Value Care
 While Incentivizing High-Value Care. Washington, DC. Nov 2019.
 Health Management Academy. Medicare Advantage Summit. Arlington, VA. Nov 2019.
 State of Connecticut High Deductible Health Plan Task Force. Hartford, CT. Dec 2019.
 American College of Cardiology Benefit Design Summit. Washington, DC. Dec 2019.
 National Alliance of Healthcare Purchaser Coalitions. Preventive Care Benefits Guidance
 Webinar. Dec 2019.
 Virginia Center for Health Innovation. Clinical Learning Series. Ann Arbor, MI. Jan 2020.
 NEBGH. V-BID X for Employers, Webinar. Jan 2020.
 Smarter Health Care Coalition Congressional Briefing. Washington, DC. Jan 2020.
 AHIP Medicare Advantage Congressional Briefing. Washington, DC. Jan 2020.
 National Academy of Medicine. Value Incentives & Systems Action Collaborative Meeting.
 Washington, DC. Feb 2020.
 Health Resources and Services Administration. Advisory Committee on Interdisciplinary,
 Community-Based Linkages. Washington, DC. Feb 2020.
 Montana Health Co-Op Board Meeting. Webcast. Apr 2020.
 Centers for Disease Control and Prevention. Quarter 2 Million Hearts® Cardiac Rehabilitation
 Collaborative (CRC) Meeting. May 2020.
 Washington Health Alliance. Webinar. Jun 2020.
 The Value in Cancer Care Consortium. 1st International Summit on Interventional
 Pharmacoeconomics. Jun 2020.
 Florida Alliance for Healthcare Value. Summer Education Series: Eliminating Low Value Care
 While Incentivizing High Value Care. Jul 2020.
 Virginia All Payer Claims Database Advisory Committee. Web presentation. Aug 2020.
 Center for Value-Based Insurance Design and Smarter Health Care Coalition. Increasing
 Access to Necessary Care During the COVID-19 Pandemic & Beyond. Webinar.
 Aug 2020.
 National Association of Health Data Organizations. Using APCDs to Measure Low Value Care.
 Web presentation. Aug 2020.
 America's Health Insurance Plans. National Conference on Medicare, Medicaid & Dual
 Eligibles. Emerging Trends in Value-Based Care---A Policy and Technology
 Perspective. Web presentation. Aug 2020.
 Defense Health Board. TRICARE Modernization Working Group. Web presentation.
 Sep 2020.

Medscape. Expert Perspectives in Preventative Screening for CRC. Web presentation. Sep 2020. <https://www.medscape.org/viewarticle/939478>.

Economic Alliance for Michigan. Health Purchaser Forum. Web presentation. Sep 2020.

Pittsburgh Business Group on Health. Annual Meeting. Web presentation. Sep 2020.

Integrated Benefit Institute. The Conference Board Healthcare Conference. Web presentation. Sep 2020.

Mid-American Coalition on Health Care. 8th Annual Health and Productivity Forum. Web presentation. Oct 2020.

National Heart, Lung, and Blood Institute, National Institutes of Health. In the U.S., Why has Blood Pressure Control Declined Nationally and What Solutions Will Improve Blood Pressure Control? Web workshop, Co-Chair. Oct 2020.

Midwest Business Group on Health / Mid-American Coalition on Health Care. The Value of Authorized Generics. Webinar. Oct 2020.

Research Consortium for Health Care Value Assessment. Higher Health Care Value Post COVID-19. Webinar. Oct 2020.

Program in Health Economics and Outcomes Research Methodologies, University of Washington. Web presentation. Oct 2020.

Coalition Against Surprise Medical Billing Hill Briefing. Webinar. Oct 2020.

Million Hearts Cardiac Rehabilitation Think Tank: Advancing New Care Models. Web presentation. Oct 2020.

Community Oncology Alliance. Applying Value-Based Insurance Design in Oncology. Web presentation. Oct 2020.

Population Health Alliance Innovation Summit. Web presentation. Oct 2020.

Center for Value-Based Insurance Design and Centers for Medicare & Medicaid Services. Virtual Roundtable with CMS Administrator Seema Verma. Webinar. Oct 2020.

American Academy of Actuaries. COVID-19 and the Future of Health Care Delivery and Payment. Web presentation. Nov 2020.

National Alliance of Health Annual Forum. Adapting Design Strategies During the COVID-19 Era. Web presentation. Nov 2020.

Association for Accessible Medicines Great Speakers Series. Eliminating Low Value Care While Incentivizing High Value Care. Web presentation. Nov 2020.

Network of Digital Evidence. NODE.Health Digital Medicine Conference. Web presentation. Dec 2020.

Centers for Medicare & Medicaid Services. Increasing Uptake of COVID-19 Vaccine. Web presentation. Dec 2020.

Altarum Healthcare Value Hub Webinar. The Marathon After the Sprint: Ensuring Value & Equity in the Future of Telehealth. Webinar. Dec 2020.

VuMedi. Reducing COVID-19 Vaccine Hesitancy: Why Is This Important? Recorded presentation. Dec 2020.

Alliance of Community Health Plans. COVID-19 Vaccine Adherence. Webinar presentation. Jan 2021.

America's Health Insurance Plans. Successfully Navigating the Value-Based Insurance Design (VBID) Model. Webinar presentation. Feb 2021.

Million Hearts: Value-Based Insurance Design Opportunities for Cardiovascular Disease Prevention and Management. Webinar presentation. Feb 2021.

District of Columbia Health Benefit Exchange Authority. Social Justice & Health Disparities Working Group Meeting. Web presentation. Feb 2021.

Employee Benefits Research Council. The Conference Board. Web presentation. Mar 2021.

Employee Benefits Council. The Conference Board. Web presentation. Mar 2021.

All-Payer Claims Database Council Learning Network. Web presentation. April 2021.
 America's Health Insurance Plans and U.S. Office of Personnel Management. Federal Employees Health Benefits Program Carrier Conference. Web presentation. April 2021.
 Milliman MedInsight. Advancements in Quantifying Low-Value Care Opportunity: Reducing Harmful Cascades of Care. Web presentation. May 2021.
 Agilon Medical Director & Pod Leader Retreat. Web presentation. May 2021.
 Purchaser Business Group on Health Primary Care Payment Reform Workgroup: Benefit Design Change. Web presentation. June 2021.
 Congressional Doctors Caucus, Washington DC. Web presentation. July 2021.
 Kansas Business Group on Health Roundtable. Web presentation. July 2021.
 Exact Sciences Evidence Update. Web presentation. July 2021.
 Reuters. The role of early detection as part of a comprehensive population health management strategy. Web presentation. July 2021.
 Patients Rising Summer Learning Series. Congressional Deskside Briefing: Drug Prices. Web presentation. July 2021.

Local (selected since 2015)

“Value Based Insurance Design”

CHRT Policy Fellowship. Center for Healthcare Research & Transformation. Ann Arbor, MI. Feb 2015.
 Michigan Association of Health Underwriters (MAHU). Okemos, MI. Oct 2015.
 West Michigan Association of Health Underwriters. Grand Rapids, MI. Mar 2016.
 Michigan Association of Health Plans Summer Conference. Acme, MI. Jul 2016.
 Midwest Social/Administrative Pharmacy Conference. Ann Arbor, MI. Aug 2016.
 Healthcare Financial Management Association. Plymouth, MI. Oct 2016.
 UAW Retiree Medical Benefits Trust. Detroit, MI. Oct 2016.
 CHRT Policy Fellowship. Center for Healthcare Research & Transformation. Ann Arbor, MI. Feb 2017.
 Michigan Association of Health Plans Summer Conference. Acme, MI. Jul 2017.
 Midwest AMCP 9th Annual Day of Education. Plymouth, MI. Sept 2017.
 IHPI National Advisory Board Meeting. Ann Arbor, MI. Oct 2017.
 Michigan Radio, Stateside. <http://vbidcenter.org/stateside-interview/>. Ann Arbor, MI. Feb 2018.
 CHRT Policy Fellowship. Center for Healthcare Research & Transformation. Ann Arbor, MI. Feb 2018.
 Henry Ford Health System. Detroit MI. May 2018.
 Henry Ford Health System Internal Medicine Grand Rounds. Detroit, MI. Sept 2018.
 CHRT Policy Fellowship. Center for Healthcare Research & Transformation. Ann Arbor, MI. Feb 2019.
 Economic Alliance for Michigan Health Purchaser Forum. Detroit, MI. May 2019.
 Trinity Health Annual Payer Strategies and Product Development Summit. Ypsilanti, MI. Jul 2019.
 CHRT Policy Fellowship. Center for Healthcare Research & Transformation. Ann Arbor, MI. Feb 2020.
 ICLE Health Law Institute. Plymouth, MI. Mar 2020.
 Michigan State of Reform Health Policy Conference. An Honest Conversation About Cost Drivers. Web presentation. May 2021.

Bibliography

Peer-Reviewed Publications

1. Bloom BS, Fendrick AM. Waiting for Care Queuing and Resource Allocation. *Med Care.* 1987;25(2):131-9.
2. Bloom BS, Fendrick AM, Ramsey SD. Changes in Peptic Ulcer Disease and Gastritis/Duodenitis in Great Britain 1970-1985. *J Clin Gastroenterol.* 1990;12(1):100-8.
3. Lee TH, Cook EF, Fendrick AM, Shammash JB, Wolfe EP, Weisberg MC, Goldman L. Impact of Initial Triage Decision on Nursing Intensity in Patients with Chest Pain. *Med Care.* 1990;28(8):737-45.
4. Fendrick AM, de Pouvourville G, Bitker C, Pelletier G. Treatment of Symptomatic Cholelithiasis in France: A Decision Analysis comparing Cholecystectomy and Biliary Lithotripsy. *Int J Technol Assess Health Care.* 1992;8(1):166-84.
5. Hillman AL, Bloom BS, Fendrick AM, Schwartz JS. Cost and Quality Effects of Alternative Treatments for Persistent Gastroesophageal Reflux Disease. *Arch Intern Med.* 1992;152(7):1467-72.
6. Fendrick AM, Javitt JC, Chiang YP. Cost-Effectiveness of the Screening and Treatment of Diabetic Retinopathy. *Int J Technol Assess Health Care.* 1992;8(4):694-707.
7. Gelijns AC, Fendrick AM. Dynamics of Innovation on Minimally Invasive Therapy. *Health Policy.* 1993;23(1-2):153-66.
8. Bloom BS, Hillman AL, Fendrick AM, Schwartz JS. A Reappraisal of Hepatitis B Vaccination Using Cost-Effectiveness Analysis. *Ann Intern Med.* 1993;118(4):298-306.
9. Fendrick AM, Gleeson SP, Cabana MD, Schwartz JS. Asymptomatic Gallstones Revisited: Is There a Role for Laparoscopic Cholecystectomy? *Arch Fam Med.* 1993;2(9):959-968.
10. Fendrick AM, Ridker PM, Bloom BS. Improved Health Benefits of Increased Use of Thrombolytic Therapy. *Arch Intern Med.* 1994;154(14):1605-9.
11. Fendrick AM, Escarce JJ, McClane C, Shea JA, Schwartz JS. Hospital Adoption of Laparoscopic Cholecystectomy. *Med Care.* 1994;32(10):1058-63.
12. Trobe JD, Fendrick AM. The Effectiveness Initiative Part 1: Medical Practice Guidelines. *Arch Ophthalmol.* 1995;113(6):715-717.
13. Fendrick AM, Goodman CS, Trobe JD. The Effectiveness Initiative Part 2: The Spectrum of Effectiveness Research. *Arch Ophthalmol.* 1995;113(7):862-865.
14. Fendrick AM. Clinical and Economic Assessment of New Surgical Technologies. *J Natl Cancer Inst.* 1995;(19):57-60.
15. Feld S, Pritzker JG, Lockett AR, Fendrick AM, et al. A Case-Based Review of the AACE Clinical Practice Guidelines for the Management of Thyroid Disease. *J Clin Outcomes Manag.* 1995;2:29-38.
16. Fendrick AM, Chernew ME, Hirth RA, Bloom BS. Alternative Management Strategies for Patients with Suspected Peptic Ulcer Disease. *Ann Intern Med.* 1995;123(4):260-268.
17. Fennerty M, Castell D, Fendrick AM, Halpern M, Johnson D, Kahrilas P, Lieberman D, Richter J, Sampliner R. The Diagnosis and Treatment of GERD in a Managed Care Environment. Suggested Disease Management Guidelines. *Arch Intern Med.* 1996;156(5):477-484.
18. Bloom BS, Fendrick AM, McClane C. Predicting Effects of Minimally Invasive Therapy. *Health Policy.* 1996;35(2):179-187.
19. Bloom BS, Fendrick AM. The Tension Between Cost Containment and the Underutilization of Effective Health Services. *Int J Technol Assess Health Care.* 1996;12(1):1-8.
20. Fendrick AM, Chernew ME, Hirth RA, Menon D. Understanding the Behavioral Response to Medical Innovation. *Am J Manag Care.* 1996;2(7)793-799.

21. Scheiman JM, Conaway DC, Fendrick AM. Optimizing Outcomes for Patients at Risk for NSAID-Induced Ulcer Disease. *J Clin Outcomes Manag.* 1996;3(5):23-36.
22. Bloom BS, Fendrick AM. Timing and Timeliness in Medical Care Evaluation. *Pharmacoeconomics.* 1996;9(3):183-187.
23. Fendrick AM, Hirth RA, Chernew ME. Differences Between Generalist and Specialist Physicians Regarding *Helicobacter pylori* and Peptic Ulcer Disease. *Am J Gastroenterol.* 1996;91(8):1544-1548.
24. Bloom BS, Fendrick AM, Chernew ME, Patel P. Clinical and Economic Effects of Mupirocin on Preventing *Staphylococcus aureus* in Hemodialysis Patients. *Am J Kidney Dis.* 1996;27(5):687-694.
25. Hirth RA, Fendrick AM, Chernew ME. Specialist and Generalist Physicians' Adoption of Antibiotic Therapy to Eradicate *Helicobacter pylori* Infection. *Med Care.* 1996;34(12):1199-1204.
26. Olson AD, Fendrick AM, Deutsch D, Chernew ME, Hirth RA, Patel C, Bloom B. Evaluation of Initial Non-Invasive Therapy in Pediatric Patients Presenting with Suspected Ulcer Disease. *Gastrointest Endosc.* 1996;44(5):554-561.
27. Fendrick AM, Chernew ME, Hirth RA, Bloom BS. Immediate Endoscopy or Initial *Helicobacter pylori* Serological Testing for Suspected Ulcer Disease: Estimating Cost-Effectiveness Using Decision Analysis. *Yale J Biol Med.* 1996;69(2):187-195.
28. McDonnell WM, Lok AS, Fendrick AM. Diagnostic and Treatment Strategies in Hepatitis C Virus Infection. *J Clin Outcomes Manag.* 1996;3(6):15-24.
29. Chernew ME, Fendrick AM, and RA Hirth. Managed Care and Medical Technology: Implications for Health Care Cost Growth. *Health Aff.* 1997;16(2):196-206.
30. Krumholz HM, Fendrick AM, Williams C, Hynes WM. Differences in Physician Compensation for Cardiovascular Services by Age, Sex, and Race. *Am J Manag Care.* 1997;3(4):557-563.
31. Fendrick AM. Outcomes Research in *Helicobacter pylori* Infection. *Aliment Pharmacol Ther.* 1997;11(1):95-101.
32. Fendrick AM, McCort JT, Chernew ME, Hirth RA, Patel C, Bloom BS. Immediate Eradication of *Helicobacter pylori* in Patients with Previously Documented Peptic Ulcer Disease: Clinical and Economic Effects. *Am J Gastroenterol.* 1997;92(11):2017-2024.
33. De Pouvourville G, Ribet-Reinhart N, Fendrick AM, Houry S, Testas P, Huguier M. Prospective Comparison of Costs and Morbidity of Laparoscopic versus Open Cholecystectomy. *Hepatogastroenterology.* 1997;44(13):35-39.
34. Scanlon DP, Chernew M, Sheffler S, Fendrick AM. Health Plan Report Cards: Exploring Differences in Plan Ratings. *Jt Comm J Qual Improv.* 1998;24(1):5-20.
35. Fendrick, AM, Chey, W. Approach to the Patient with *Helicobacter pylori* - Associated Epigastric Pain. *J Clin Outcomes Manag.* 1998;5(1)41-48. Reprinted in *Hosp Physician.* 1998;34(2):36-44.
36. Laine L, Fendrick AM. *Helicobacter pylori* and Peptic Ulcer Disease. Bridging the Gap Between Knowledge and Treatment. *J Postgrad Med.* 1998;103(3):231-243.
37. Moss SF, Fendrick AM, Cave DR, Modlin IM. *Helicobacter pylori* - More Light, Less Heat. *Am J Gastroenterol.* 1998;93(3):306-310.
38. Dwamena BA, Kloos RT, Fendrick AM, Gross MD, Francis IR, Korobkin MT, Shapiro B. Diagnostic Evaluation of the Adrenal Incidentaloma: Decision and Cost-Effectiveness Analysis. *J Nucl Med.* 1998;39(4):707-712.
39. Chernew ME, Hirth RA, Sonnad SS, Ermann R, Fendrick AM. Managed Care, Medical Technology, and Health Care Cost Growth: A Review of the Evidence. *Med Care Res Rev.* 1998;55(3):259-288.

40. Moyer CA, Fendrick, AM. Measuring Health Related Quality of Life in Patients with Upper Gastrointestinal Disease. *Dig Dis.* 1998;16(5):315-324.
41. Fendrick AM. Assessing the Cost Effectiveness of Analgesic Therapy. *Managing Chronic Pain. Postgraduate Medicine a Special Report.* 1998;S50-55.
42. Fendrick AM, Chernew ME, Hirth RA, Bloom BS, Bandekar RR, Scheiman JM. Clinical and Economic Effects on Population-Based *Helicobacter pylori* Screening to Prevent Gastric Cancer. *Arch of Intern Med.* 1999;159(2):142-148.
43. Fendrick AM, Lee JH, LaBarge C, Glick HA. Clinical and Economic Impact of a Combination *Haemophilus influenzae* and Hepatitis B Virus Vaccine. *Arch of Pediatr Adolesc Med.* 1999;153(2):126-136.
44. Bloom BS, Tibi-Levy Y, Harari A, Fendrick, AM. Direct Medical Care Costs of Unstable Angina Pectoris in a Defined Population. *J Manag Care Spec Pharm.* 1999;5(1):39-44.
45. Fendrick AM, Blitz SG. Gastroesophageal Reflux: Therapy Consideration After Failure of Low- Dose, Nonprescription H2RAs. *Formulary.* 1999;34(3):234-246.
46. Graham DY, Rakel RE, Fendrick AM, Go MF, Marshall BJ, Peura DP, Scherger JS. Scope and Consequences of Peptic Ulcer Disease: How Important is Asymptomatic *Helicobacter pylori* Infection? *J Postgrad Med.* 1999;105(3):100-110.
47. Graham DY, Rakel RE, Fendrick AM, Go MF, Marshall BJ, Peura DP, Scherger JS. Recognizing Peptic Ulcer Disease: Keys to Clinical and Laboratory Diagnosis. *J Postgrad Med.* 1999;105(3):113-133.
48. Graham DY, Rakel RE, Fendrick AM, Go MF, Marshall BJ, Peura DP, Scherger JS. Practical Advice on Eradicating *Helicobacter pylori* Infection: Treating Peptic Ulcer Disease Cost-Effectively. *J Postgrad Med.* 1999;105(3):137-148.
49. Fendrick AM, Blitz SG, Reilly JP. Management Strategies for Patients with Symptomatic Gastroesophageal Reflux Disease in the OTC H2-Antagonist Era. *J Clin Outcomes Manag.* 1999;6(4):55-64.
50. Hirth RA, Bloom BS, Chernew ME, Fendrick, AM. Willingness to Pay for Diagnostic Certainty: A Comparison Among Patients, Physicians, and Managers. *J Gen Intern Med.* 1999;14(3):193-195.
51. Dent J, Brun J, Fendrick AM, Fennerty M, Janssens J, Kahrilas P, Lauritsen K, Reynolds J, Shaw M, Talley N. An Evidence-Based Appraisal of Reflux Disease Management - The Genval Workshop Report. *Gut.* 1999;44(Suppl 2): S1-S16.
52. Fendrick AM, Chey WD, Magaret N, Palaniappan J, Fennerty MB. Symptom Status and the Desire for *Helicobacter pylori* Confirmatory Testing After Eradication Therapy in Patients with Peptic Ulcer Disease. *Am J Med.* 1999;107(2):133-136.
53. Trobe JD, Sieving PC, Guire KE, Fendrick AM. The Impact of the Optic Neuritis Treatment Trial on the Practices of Ophthalmologists and Neurologists. *Ophthalmol.* 1999;106(11):2047-2053.
54. Moyer CA, Stern DT, Katz SJ, Fendrick AM. "We Got Mail". Electronic Communication Between Physicians and Patients: Implications for Managed Care. *Am J Manag Care.* 1999;5(12):1513-1522.
55. Cram P, Blitz SG, Monto A, Fendrick AM. Diagnostic Testing for Influenza: Review of Current Status and Implications of Newer Treatment Options. *Am J Manag Care.* 1999;5(12):1555-1561.
56. Teitelbaum F, Roe CM, Fendrick AM. Pharmacy Management Trends: A Guide for New Physicians. *Semin Med Pract.* 2000;3(1):22-31.
57. Blitz SG, Fendrick AM, Chenoweth C. Developments in the Care of Influenza: Priorities and Perspectives. *J Clin Outcomes Manag.* 2000;7(2):63-72.

58. Rich M, Scheiman JM, Tierney W, Fendrick AM. Is Upper Gastrointestinal Radiography a Cost- Effective Alternative to a *Helicobacter pylori* "Test and Treat" Strategy for Patients with Suspected Peptic Ulcer Disease? *Am J Gastroenterol.* 2000; 95(3):651-8.
59. Monto AS, Fendrick AM. Developments in Influenza Prevention and Treatment: A Managed Care Perspective. *Dis Manag Health Outcomes.* 2000;7(5):1-10.
60. Hirth RA, Bloom BS, Chernew ME, Fendrick AM. Patient, Physician, and Payer Perceptions and Misperceptions of Willingness to Pay for Diagnostic Certainty. *Int J Technol Assess Health Care.* 2000;16(1):35-49.
61. Peterson WL, Fendrick AM, Cave DR, Peura DA, Garabedian-Ruffalo, SM, Laine L. *Helicobacter pylori*-Related Disease: Guidelines for Testing and Treatment. *Arch Intern Med.* 2000;160(9):1285-1291.
62. Tierney WM, Fendrick AM, Hirth RA, and Scheiman JM. The Clinical and Economic Impact of Alternative Staging Strategies for Adenocarcinoma of the Pancreas. *Am J Gastroenterol.* 2000;95(7):1708-1713.
63. Hirth RA, Chernew ME, Miller E, Fendrick AM, Weissert WG. Willingness to Pay for a QALY: In Search of a Standard. *Med Decis Making.* 2000;20(3):332-342.
64. Stern MA, Fendrick AM, McDonnell WM, Gunaratnam N, Moseley R, Chey WD. A Randomized, Controlled Trial to Assess a Novel Colorectal Cancer Screening Strategy: The Conversion Strategy. *Am J Gastroenterol.* 2000;95(8):2074-2079.
65. Saint S, Veenstra DL, Sullivan SD, Chenoweth C, Fendrick AM. The Potential Clinical and Economic Benefits of Silver Alloy Urinary Catheters in Preventing Urinary Tract Infection. *Arch Intern Med.* 2000;160(17):2670-2675.
66. Koff RS, Fendrick AM. Pharmacoeconomics of Hepatitis C. *Pharmacol Ther.* 2000; 25(9):468-475.
67. Chenoweth CE, Saint S, Martinez F, Lynch JP, Fendrick AM. The Evolution of Antimicrobial Resistance in *Streptococcus Pneumoniae*: Implications for the Treatment of Community-Acquired Pneumonia. *Mayo Clinic Proceedings.* 2000; 75(11):1161-1168.
68. Chernew MC, Cowen ME, Kirking DM, Smith DG, Valenstein P, Kostoff L, Fendrick AM. Pharmaceutical Cost Growth Under Capitation. *Health Aff.* 2000;19(6):266-276.
69. Nallamotheu BK, Fendrick AM, Rubenfire M, Saint S, Bandekar RR, Omenn GS. Potential Clinical and Economic Effects of Homocyst(e)ine Lowering. *Arch Intern Med.* 2000;160(22):3406-3412.
70. Barnett A, Birnbaum H, Cremieux PY, Fendrick AM, Slavin M. The Costs of Cancer to a Major Employer in the United States: A Case-Control Analysis. *Am J Manag Care.* 2000; 6(11):1243-1251.
71. Bloom BS, de Pouvourville N, Libert S, Fendrick AM. Surgeon Predictions on Growth of Minimal Invasive Therapy: The Difficulty of Estimating Technologic Diffusion. *Health Policy.* 2000;54(3):201-207.
72. Fendrick AM. The Role of Economic Evaluation in the Diagnosis and Treatment of *Helicobacter pylori* Infection. *Gastroenterol Clin N.* 2000;29(4):837-851.
73. Oral H, Knight BP, Sticherling C, Kim MH, Pelosi F, Michaud GF, Fendrick AM, Strickberger SA, Morady F. Cost Analysis of Transthoracic Cardioversion of Atrial Fibrillation with and Without Ibutilide Pretreatment. *J Cardiovasc Pharm T.* 2000;5(4):259-266.
74. Scheiman JM, Bandekar RR, Chernew ME, Fendrick AM. *H pylori* Screening for Individuals Requiring Chronic NSAID Therapy: A Decision Analysis. *Aliment Pharm Ther.* 2001;15(1):63-71.
75. Shaw MJ, Talley NJ, Beebe TJ, Rockwood T, Carlsson R, Adlis S, Fendrick AM, Jones R, Dent J. The Development and Initial Validation of a Brief Diagnostic Questionnaire for Gastroesophageal Reflux Disease. *Am J Gastroenterol.* 2001;96(1):52-57.

76. Flaherty K, Saint S, Fendrick AM, Martinez FJ. The Spectrum of Patients with Acute Bronchitis: Using Baseline Factors to Guide Empiric Therapy. *Post Grad Med.* 2001;109(2):39-47.
77. Groeneveld PW, Lieu TA, Fendrick AM, Hurley LB, Ackerson LM, Levin TR, Allison JE. Quality of Life Measurement Clarifies the Cost-Effectiveness of *Helicobacter pylori* Eradication in Peptic Ulcer Disease and Uninvestigated Dyspepsia. *Am J Gastroenterol.* 2001;96(2):338-47.
78. Saint S, Flaherty KR, Abrahamse P, Martinez FJ, Fendrick AM. Acute Exacerbation of Chronic Bronchitis: Disease-Specific Attributes that Influence the Cost-Effectiveness of Therapy. *Clin Ther.* 2001;23(3):1-14.
79. Cram P, Blitz SG, Monto A, Fendrick AM. Influenza: Cost of Illness and Considerations in the Economic Evaluation of New and Emerging Therapies. *Pharmacoeconomics.* 2001;19(3):223 - 230.
80. Nallamothu BK, Saint S, Bielak LF, Rubenfire M, Peyser P, Sonnad S, Fendrick AM. Electron-Beam Computed Tomography in the Diagnosis of Coronary Artery Disease: A Meta-Analysis of the Literature. *Arch Intern Med.* 2001;161(6):833-838.
81. Shaw MJ, Fendrick AM, Kane RL, Adis SA, Talley NJ. Self-Report of Efficacy and Presentation Rate to Physicians in Users of Over-The-Counter Histamine 2-Antagonists. *Am J Gastroenterol.* 2001;96(3):673-677.
82. Hayman JA, Langa KM, Kabeto MU, Katz SJ, DeMonner SM, Chernew ME, Slavin MB, Fendrick AM. Estimating the Cost of Informal Caregiving for Elderly Patients with Cancer. *J Clin Onc.* 2001;19(13):3219-3225.
83. Chernew M, Smith DG, Kirking DM, Fendrick AM. Decomposing Pharmaceutical Cost Growth in Different Types of Health Plans. *American J of Managed Care.* 2001;7(7):667-73.
84. Ladabaum U, Fendrick AM, Scheiman JM. Outcomes of initial *H pylori* Testing in US Primary Care Patients with Uninvestigated Dyspepsia. *Am J Gastroenterol.* 2001;96(7):2051-2057.
85. Fendrick AM, Baldwin JL. Allergen-Induced Inflammation and the Role of IgE. *Am J Ther.* 2001;8(4):291-297.
86. Fendrick AM. Management of Patients with Symptomatic Gastroesophageal Reflux Disease: Primary Care Perspective. *Am J Gastroenterol.* 2001;96(8): Suppl 29-33.
87. Nallamothu BK, Saint S, Saha S, Fendrick AM, Kelley K, Ramsey SD. Coronary Artery Bypass Grafting in Native Americans: Higher Risk of Death Compared to Other Ethnic Groups? *J Gen Intern Med.* 2001;16(8):554-558.
88. Fendrick AM, Smith DG, Chernew ME, Shaw SN. A Benefit-Based Copay for Prescription Drugs: Patient Contribution Based on Total Benefits, Not Drug Acquisition Cost. *Am J Manag Care.* 2001;7(9):861-867.
89. Carlos R, Bree R, Abrahamse P, Fendrick AM. Cost-Effectiveness of Saline-Assisted Hysterosonography and Office Hysteroscopy in Evaluating Post-Menopausal Bleeding: A Decision Analysis. *Acad Radiol.* 2001;8(9):879-87.
90. Chey W, Fendrick AM. Non-Invasive *H. pylori* Testing for the "Test and Treat" Strategy: A Decision Analysis to Assess the Impact of Past Infection on Test Choice. *Arch Intern Med.* 2001;161(17):2129-32.
91. Saint S, Chenoweth C, Fendrick AM. The Role of Economic Evaluation in Infection Control. *Am J Infect Control.* 2001;29(5):338-44.
92. Ladabaum U, Chopra CL, Huang G, Chernew ME, Scheiman JM, Fendrick AM. Aspirin as an Adjunct to Screening for Prevention of Sporadic Colorectal Cancer. *Ann Intern Med.* 2001;135(9):769-781.
93. Axelrod, DA, Fendrick AM, Wennberg DE, Birkmeyer JD, Siewers AE. Cardiologists Performing Peripheral Angioplasties: Impact on Utilization. *Effect Clin Prac.* 2001;4(5):191-98.

94. Langa K, Kabeto M, Chernew M, Ofstedal MB, Herzog AR, Willis RJ, Wallace RB, Mucha LM, Straus WL, Fendrick AM. National Estimates of the Quantity and Cost of Informal Caregiving for the Elderly with Dementia. *Gen Intern Med.* 2001;16(11):770-8.
95. Olson AD, Fendrick AM, Deutsch, DE. Endoscopic Outcomes Analysis. *Gastrointest Endosc N Am.* 2001;11(4):557-68.
96. Cremieux P, Slavin MB, Fendrick AM, Hiriak T, Kosicki G. The Costs of Cancer: Cancer-Related Conditions Can Add Dramatically to Overall Costs of Care. *J Manag Care Med.* 2002;6(1):12-19.
97. Barnett A, Cremieux PY, Fendrick AM, George M, Slavin MB. Anemia-Related Costs for Cancer Patients. *J Manag Care Med.* 2002;6(1):20-28.
98. Fendrick AM, Garabedian-Ruffalo SM. A Clinicians' Guide to the Selection of NSAID Therapy. *Pharm Ther.* 2002;27(11):579-81.
99. Monto AS, Fendrick AM, Sarnes MW. Respiratory Illness Caused by Picornavirus Infection: A Review of Clinical Outcomes. *Clin Ther.* 2001;23(10):1615-1627.
100. Ellis CN, Reiter KL, Bandekar RR, Fendrick AM. Cost-Effectiveness Comparison of Therapy for Psoriasis with a Methotrexate-Based Regimen vs. a Rotation Regimen of Cyclosporine for Microemulsion (Neoral) and Methotrexate. *J Am Acad Dermatol.* 2002;46(2):242-50.
101. Ellis CN, Reiter KL, Wheeler JR, Fendrick AM. Economic Analysis in Dermatology. *J Am Acad Dermatol.* 2002;46(2):271-83.
102. Beutels P, Edmunds WJ, Fernando A, De Wit GA, Evans D, Feilden R, Fendrick AM, Ginsberg GM, Glick HA, Mast E, Pecjevis M, Van Doorslaier EKA, Van Hout BA. Economic Evaluation of Vaccination Programmes: A Consensus Statement Focusing on Viral Hepatitis. *Pharmacoeconomics.* 2002;20(1):1-7.
103. Shureiqi I, Cantor SB, Lippman SM, Brenner DE, Chernew ME, Fendrick AM. Clinical and Economic Impact of Multiple Gated Acquisition (MUGA) Scan Monitoring During Anthracycline Therapy. *Br J Cancer.* 2002;86(2):226-232.
104. Blitz SG, Cram P, Chernew ME, Monto AS, Fendrick AM. Diagnostic Testing or Empirical Neuraminidase Inhibitor Therapy for Patients with Influenza-Like Illness: What a Difference a Day Makes. *American Journal of Managed Care.* 2002;8(3):11-17.
105. Ollendorf DA, Fendrick AM, Kinsey K, Williams GR, Oster G. Is Sepsis Accurately Coded on Hospital Bills. *Value Health.* 2002;5(2):279-81.
106. Fendrick AM, Bandekar RR, Chernew ME, Scheiman JM. Role of Initial NSAID Choice and Patient Risk Factors in the Prevention of NSAID Gastropathy: A Decision Analysis. *Arthritis Care Res.* 2002;47(1):36-43.
107. Langa K, Vijan S, Hayward R, Chernew M, Blaum C, Kabeto M, Weir D, Katz S, Willis R, Fendrick AM. Informal Caregiving for Diabetes and Diabetic Complications Among Elderly Americans. *J Gerontol.* 2002;57(3):S177-S186.
108. Chernew ME, Gowrisankaran G, Fendrick AM, Payer Type and the Returns to Bypass Surgery: Evidence from Hospital Entry Behavior. *J Health Econ.* 2002;21(3) :451-474.
109. Hickenbottom SL, Fendrick AM, Kutcher J, Kabeto M, Katz SJ, Langa KM. A National Study of the Quantity and Cost of Informal Caregiving for the Elderly with Stroke. *Neurology.* 2002;58(12):1754-1759.
110. Cram P, Nallamotheu BK, Fendrick AM, Saint SK. Fast Food Franchises in Hospitals. (research letter) *JAMA.* 2002;287(22):2945-2946.
111. Fendrick AM. Developing an Economic Rationale for the Use of Selective COX-2 Inhibitors for Patients at Risk for NSAID Gastropathy. *Cleve Clin J Med.* 2002;69:SI59-SI64.
112. Nallamotheu BK, Fendrick AM, Omenn GS. Homocyst(e)ine and Coronary Heart Disease: Pharmacoeconomic Support for Interventions to Lower Hyperhomocyst(e)inaemia. *Pharmacoeconomics.* 2002;20(7):429-442.

113. Ladabaum U, Chey WD, Scheiman JM, Fendrick AM. Reappraisal of Non-Invasive Strategies in Uninvestigated Dyspepsia: A Cost-Minimization Analysis. *Aliment Pharm Ther.* 2002;16(8):1491-1502.
114. Nallamotheu BK, Saint S, Eagle KA, Langa K, Fendrick AM, Hogikyan RB, Kelley K, Ramsey S. Coronary Artery Bypass Grafting on Octogenarians: Clinical and Economic Outcomes at Community-Based Healthcare Facilities. *Am J Manag Care.* 2002;8(8):749-755.
115. Fendrick AM. Cost-Effective Use of NSAIDs: Issues Pertinent to Coxib Use in Managed Care. *Am J Manag Care.* 2002;8(17 Suppl):S529-S541.
116. Langa KM, Fendrick AM, Flaherty K, Ferndando M, Kabeto MU, Saint S. Informal Caregiving for Chronic Lung Disease Among Older Americans. *Chest.* 2002;122(6):2197.
117. Ladabaum U, Fendrick AM, Glidden D, Scheiman JM. Helicobacter pylori Test-and-Treat Intervention Compared to Usual Care in Primary Care Patients with Suspected Peptic Ulcer Disease in the United States. *Am J Gastroenterol.* 2002;97(12):3007-3014.
118. Inadomi JM, Sampliner R, Lagergren J, Lieberman D, Fendrick AM, Vakil N. Screening and Surveillance for Barrett's Esophagus in High-Risk Groups: A Cost-Utility Analysis. *Ann Intern Med.* 2003;138(3):176-186.
119. Fendrick AM, Monto AS, Sarnes M, Nightengale B. The Economic Burden of Non-Influenza-Related Viral Respiratory Infection in the United States. *Arch Intern Med.* 2003;163(4):487-494.
120. Carlos RC, Kim HM, Hussain HK, Nghiem HV, Francis IR, Fendrick AM. Developing a Prediction Rule to Assess Hepatic Malignancy in Patients with Cirrhosis. *Amer J Radiol.* 2003;180(4):893-900.
121. Kocs D, Fendrick AM. Effect of Off-Label Use of Oncology Drugs on Pharmaceutical Costs: The Rituximab Experience. *Am J Manag Care.* 2003;9(5):393-400.
122. Ladabaum U, Scheiman JM, Fendrick AM. Potential Effect of Cyclooxygenase-2 Specific Inhibitors on the Prevention of Colorectal Cancer: A Cost-Effectiveness Analysis. *Am J Med.* 2003;114(7):546-554.
123. Fendrick AM. Viral Respiratory Infections Due to Rhinoviruses: Current Knowledge, New Developments. *Am J Ther.* 2003;10(3):193-202.
124. Axelrod DA, Fendrick AM, Carlos RC, Lederman RJ, Froehlich JB, Weder AB, Abrahamse PH, Stanley JC. Percutaneous Stenting of Incidental Unilateral Renal Artery Stenosis: Decision Analysis of Costs and Benefits. *J Endovasc Ther.* 2003;10(3):546-556.
125. Carlos RC, Scheiman JM, Hussain HK, Song JH, Francis IR, Fendrick AM. Making Cost-Effectiveness Analyses Clinically Relevant: The Effect of Provider Expertise and Biliary Disease Prevalence on the Economic Comparison of Alternative Diagnostic Strategies. *Acad Radiol.* 2003;10(6):620-630.
126. Drummond M, Brown R, Barbieri M, Fendrick AM. Use of Pharmacoeconomics Information-Report of the ISPOR Task Force on use of Pharmacoeconomic/Health Economic Information in Health Care Decision-Making. *Value Health.* 2003;6(4):407-416.
127. Cram P, Vijan S, Wolbrink A, Fendrick AM. The Impact of Including Passive Benefits in Cost-Effectiveness Analysis: The Case of Automated External Defibrillators on Commercial Aircraft. *Value Health.* 2003;6(4):466-473.
128. Cram P, Fendrick AM, Inadomi J, Cowen ME, Carpenter D, Vijan S. The Impact of a celebrity promotional campaign on the use of colon cancer screening: The Katie Couric Effect. *Arch Intern Med.* 2003;163(13):1601-5.
129. Ubel PA, Hirth RA, Chernew ME, Fendrick AM. What is The Price of Life and Why Doesn't It Increase at the Rate of Inflation? *Arch Intern Med.* 2003;63(14):1637-41.
130. Williams LK, Pladevall M, Fendrick AM, Elston-Lafata J, McMahon L. Differences in The Reporting of Care-Related Patient Injuries to Existing Reporting Systems. *Jt Comm J Qual Saf.* 2003;29(9):460-467.

131. Cram P, Vijan S, Fendrick AM. Cost-effectiveness of Automated External Defibrillator Deployment in Selected Public Locations. *J Gen Intern Med.* 2003;18(9):1-10.
132. Inadomi JM, McIntyre L, Bernard L, Fendrick AM. Step-Down from Multiple- To Single-Dose Proton Pump Inhibitors: A Prospective Study of Patients with Heartburn or Acid Regurgitation Completely Relieved with PPIs. *Am J Gastroenterol.* 2003;98(9):1940-1944.
133. Carlos RC, Axelrod DA, Ellis J, Abrahamse PH, Fendrick AM. Incorporating Patient-Centered Outcomes in Cost-Effectiveness Analysis Imaging Strategies in Renovascular Hypertension. *Am J Radiol.* 2003;181(6):1653-1661.
134. Carpenter D, Chernew M, Smith DG, Fendrick AM. Approval Time for New Drugs: Does the Source of Funding for FDA Staff Matter? *Health Aff.* 2003;Jul-Dec;Suppl Web Exclusives:W3-618-24.
135. Fendrick AM, Shaw M, Schachtel B, Allgood L, Allgood G, Grender J, Peura D. Self-Selection and Use Patterns of Over-the-Counter Omeprazole for Frequent Heartburn. *Clin Gastroenterol Hepatol.* 2004;2(1):117-21.
136. Langa KM, Fendrick AM, Chernew ME, Kabeto MU, Paisley KL, Hayman, JA. Out-of-pocket health care expenditures Among older Americans with cancer. *Value Health.* 2004;7(2):186- 94.
137. Langa KM, Valenstein MA, Fendrick AM, Kabeto MU, Vijan S. Extent and Cost of Informal Caregiving for Older Americans with Symptoms of Depression. *Am J Psychiatry.* 2004;161(5):857- 863.
138. Song K, Fendrick AM and Ladabaum U. Fecal DNA Testing Compared with Conventional Colorectal Cancer Screening Methods: A Decision Analysis. *Gastroenterol.* 2004;126(5):1270-1279.
139. Kent DM, Fendrick AM, Langa KM. New and Dis-Improved: On the Evaluation and Use of Less Effective, Less Expensive Medical Interventions. *Med Dec Making.* 2004;24(3):281-86.
140. Banaszak-Holl J, Fendrick AM, Foster NL, Herzog AR, Kabeto MU, Kent DM, Straus WL, Langa KM. Predicting Nursing Home Admission: Estimates from A Seven Year Follow-Up of a Nationally Representative Sample of Older Americans. *Alzheimers Dement.* 2004;18(2):83-89.
141. Langa KM, Larson EB, Wallace RB, Fendrick AM, Foster NL, Kabeto MU, Weir DR, Willis RJ, Herzog AR. Out-of-Pocket Health Care Expenditures Among Older Americans with Dementia. *Alzheimers Dement.* 2004;18(2):90-98.
142. Ellis JJ, Erickson SR, Stevenson JG, Bernstein SJ, Stiles RA, Fendrick AM. Sub-optimal Statin Adherence and Discontinuation in Primary and Secondary Prevention Populations. *J Gen Intern Med.* 2004;19(6):638-645.
143. Carpenter D, Fendrick AM. Accelerating Approval Times for New Drugs in the US. *Regul Aff J – Pharma.* 2004;15(6):411-417.
144. Ladabaum U, Song K, Fendrick AM. Colorectal Neoplasia Screening with Virtual Colonoscopy: When, at What Cost, and with What National Impact? *Clin Gastroenterol Hepatol.* 2004;2(7):554-563.
145. Heisler M, Langa KM, Eby EL, Fendrick AM, Kabeto MU, Piette JD. The Health Effects of Restricting Prescription Medication Use Because of Cost. *Med Care.* 2004;42(7):626-634.
146. Fendrick AM, Garabedian-Ruffalo SM, Bernstein SJ, Scheiman JM. Does an Aspirin a Day Take the GI Benefit of a Coxib Away? *Medscape Rheum.* 2004.
147. Vijan S, Inadomi J, Hayward RA, Hofer TP, Fendrick AM. Projections of Demand and Capacity for Colonoscopy Related to Increasing Rates of Colorectal Cancer Screening in the US. *Aliment Pharmacol Ther.* 2004;20(5):507-515.
148. Carlos RC, Fendrick AM, Ellis J, Bernstein SJ. Can Breast and Cervical Cancer Screening Visits be used to enhance Colorectal Cancer Screening? *J Am Coll Radiol.* 2004;1(10):769-776.

149. Brunton S, Carmichael BP, Colgan R, Feeney AS, Fendrick AM, Quintiliani R. Chronic Bronchitis and an Acute Exacerbation of Chronic Bronchitis. *Am J Manag Care*. 2004;10(10):689- 696.
150. Chernew ME, Jacobson PD, Hofer TP, Aaronson KD, Fendrick AM. Barriers to Constraining Health Care Cost Growth. *Health Aff*. 2004;23(6):122-128.
151. Molina L, Carlos R, Fendrick AM, Abrahamse PH, Dong Q, Bernstein SJ. Completion of Colorectal Cancer Screening in Women Attending Screening Mammography. *Acad Radiol*. 2004;11(11):1237-1241.
152. Cremieux PY, Fastenau J, Kosicki G, Piech CT, Fendrick AM. Cost-Minimization Analysis of Once-Weekly Versus Thrice-Weekly Epoetin Alfa for Chemotherapy-Related Anemia. *J Manag Care Pharm*. 2004;10(6):531-37.
153. Inadomi JM, Fendrick AM. PPI Use in the OTC Era: Who to Treat, with What, and for How Long? *Clin Gastroenterol Hepatol*. 2005;3(3):208-15.
154. Carlos RC, Fendrick AM, Patterson SK, Bernstein SJ. Associations in Breast and Colon Cancer Screening Behavior in Women. *Acad Radiol*. 2005;12(4):451-458.
155. Vakil N, Fendrick AM. How to test for *Helicobacter pylori* in 2005. *Cleve Clin J Med*. 2005;72 Suppl 2:S8-S13; Discussion S14-21.
156. Chey WD, Inadomi JM, Booher AM, Sharma VK, Fendrick AM, Howden CW. Primary-Care Physicians' Perceptions and Practices on the Management of GERD: Results of a National Survey. *Am J Gastro*. 2005;100(6):1237-42.
157. Orringer JS, Fendrick AM, Trask PC, Bichakjian CK, Schwartz JN, Wang TS, Karimipour DJ, Johnson TM. The Effects of a Professionally Produced Videotape on Education and Anxiety/Distress Levels for Patients with a New Diagnosis of Melanoma: A Randomized, Prospective Clinical Trial. *J Am Acad Dermatol*. 2005;53(2):224-229.
158. Rosen AB, Hamel MB, Weinstein MC, Cutler D, Fendrick AM, Vijan S. Cost-Effectiveness of Full Medicare Coverage of Angiotensin-Converting Enzyme Inhibitors for Beneficiaries with Diabetes. *Ann of Intern Med*. 2005;143(2):89-99.
159. McMahan LF, Hayward RA, Saint S, Chernew M, Fendrick AM. Univariate Solutions in a Multivariate World: Can We Afford to Practice Like the "Good Old Days"? *Am J Manag Care*. 2005;11(8):473-6.
160. Scheiman JM, Fendrick AM. Practical Approaches to Minimizing Gastrointestinal and Cardiovascular Safety Concerns with COX-2 Inhibitors and NSAIDs. *Arthritis Res Ther*. 2005;7 Suppl 4:S23-S29.
161. Fendrick AM. Assessing the Gastrointestinal Complications of Over-the-Counter Analgesics. *Fam Pract Recert*. 2005;27(10):9-15.
162. Jones E, Vijan S, Fendrick AM, Deshpande S, Cram P. Automated External Defibrillator Deployment in High Schools and Senior Centers. *Prehosp Emerg Care*. 2005;9(4):382-385.
163. Carlos RC, Fendrick AM, Abrahamse PH, Dong Q, Patterson S, Bernstein SJ. Colorectal Cancer Screening Behavior in Women Attending Screening Mammography: Longitudinal Trends and Predictors. *Womens Health Issues*. 2005;15(6):249.
164. Chey WD, Eswaran S, Howden CW, Inadomi JM, Fendrick AM, Scheiman JM. Primary Care Physician Perceptions of NSAID and Aspirin-Associated Toxicity: Results of a National Survey. *Aliment Pharmacol Ther*. 2006;23(5):655-68.
165. Chernew ME, Rosen AB, Fendrick AM. Rising Out-of-Pocket Costs in Disease Management Programs. *Am J Manag Care*. 2006;12(3):150-4.
166. Chan PS, Stein K, Chow T, Fendrick AM, Bigger JT, Vijan S. Cost-Effectiveness of a Microvolt T-wave Alternans Screening Strategy for ICD Placement in the MADIT-II Eligible Population. *J Am Coll Cardiol*. 2006;48(1):112-21.

167. Stecker EC, Fendrick AM, Knight BP, Aaronson KD. Prophylactic Pacemaker Use to Allow Beta Blocker Therapy in Chronic Heart Failure Patients with Bradycardia. *Am Heart J*. 2006;151(4):820-8.
168. Menees S, Carlos RC, Scheiman JM, Fendrick AM. Gastroenterologists utilize the referral for EGD to Enhance Colon Cancer Screening More Effectively than Primary Care Physicians. *Aliment Pharmacol Ther*. 2006;23(7):953-62.
169. De Smet BD, Fendrick AM, Stevenson JG, Bernstein SJ. Over and Under Utilization of COX-2 Selective Inhibitors by Primary Care Physicians and Specialists: The Tortoise and The Hare Revisited. *J Gen Intern Med*. 2006;21(7):694-7.
170. Cram P, Katz D, Vijan S, Kent DM, Langa KM, Fendrick AM. Implantable or External Defibrillators for Individuals at Increased Risk of Cardiac Arrest: Where Cost-Effectiveness Hits Fiscal Reality. *Value Health*. 2006;9(5):292-302.
171. Brown DL, Fahmi AS, Lisabeth LD, Farnie MA, Colletti LA, Langa KM, Fendrick AM, Garcia NM, Smith MA, Morgenstern LB. Defining Cause of Death in Stroke Patients: The Brain Attack Surveillance in Corpus Christi Project. *Am J Epidemiol*. 2006;12(7):1-6.
172. Fendrick AM, Chernew ME. Value-based Insurance Design: Aligning Incentives to Bridge the Divide Between Quality Improvement and Cost Containment. *Am J Manag Care*. 2006;12 SP5-SP10.
173. Scheiman JM, Fendrick AM. Summing the Risk of NSAID Therapy. *Lancet*. 2007;369(9573):1580-1.
174. Fendrick AM, Chernew ME. "Fiscally Responsible, Clinically Sensitive" Cost Sharing: Contain Costs While Preserving Quality. *Am J Manag Care*. 2007;13(6 Pt 2):325-7.
175. Fendrick AM, Chernew ME. Value-Based Insurance Design: A "Clinically Sensitive, Fiscally Responsible" Approach to Mitigate the Adverse Clinical Effects of High-Deductible Consumer-Directed Health Plans. *J Gen Intern Med*. 2007;22(6):890-1.
176. Chernew ME, Rosen AB, Fendrick AM. Value-Based Insurance Design. *Health Aff*. 2007;26(2):w195-w203.
177. Brown DL, Al-Senani F, Lisabeth LD, Farnie MA, Colletti LA, Langa KM, Fendrick AM, Garcia NM, Smith MA, Morgenstern LB. Defining Cause of Death in Stroke Patients: The Brain Attack Surveillance in Corpus Christi Project. *Am J Epidemiol*. 2007;165(5):591-6.
178. Chernew ME, Shah MR, Wegh A, Rosenberg SN, Juster IA, Rosen AB, Sokol MC, Yu-Isenberg K, Fendrick AM. Impact of Decreasing Copayments on Medication Adherence Within a Disease Management Environment. *Health Aff (Millwood)*. 2008;27(1):103-12.
179. Fendrick AM, Pan DE, Johnson GE. OTC Analgesics and Drug Interactions: Clinical Implications. *Osteopath Med Prim Care*. 2008; 2:2.
180. Parekh M, Fendrick AM, Ladabaum U. As Tests Evolve and Costs of Cancer Care Rise: Reappraising Stool-Based Screening for Colorectal Neoplasia. *Aliment Pharmacol Ther*. 2008;27(8):697-712.
181. Brown CD, Benditt JO, Sciruba FC, Lee SM, Criner GJ, Mosenifar Z, Shade DM, Slivka WA, Wise RA; National Emphysema Treatment Trial Research Group. Exercise Testing in Severe Emphysema: Association with Quality of Life and Lung Function. *COPD*. 2008;5(2):117-24.
182. Chernew ME, Shah MR, Wegh A, Rosenberg SN, Juster IA, Rosen AB, Fendrick AM. Confronting Hysteria: A Reply to Fairman and Curtiss. *J Manag Care Pharm*. 2008;14(3):324-6; author reply 326-8.
183. Pan F, Chernew ME, Fendrick AM. Impact of Fixed-Dose Combination Drugs on Adherence to Prescription Medications. *J Gen Intern Med*. 2008;23(5):611-4
184. Chernew M, Gibson TB, Yu-Isenberg K, Sokol MC, Rosen AB, Fendrick AM. Effects of Increased Patient Cost Sharing on Socioeconomic Disparities in Health Care. *J Gen Intern Med*. 2008;23(8):1131-6.

185. Kerber KA, Meurer WJ, West BT, Fendrick AM. Dizziness Presentations in U.S. Emergency Departments, 1995-2004. *Acad Emerg Med.* 2008;15(8):744-50.
186. Saini SD, Schoenfeld P, Fendrick AM, Scheiman J. Cost-Effectiveness of Proton Pump Inhibitor Co-Therapy in Patients Taking Long-Term, Low-Dose Aspirin for Secondary Cardiovascular Prevention. *Arch Intern Med.* 2008;168(15):1684-90; discussion 1691.
187. Elnachef N, Scheiman JM, Fendrick AM, Howden CW, Chey WD. Changing Perceptions and Practices Regarding Aspirin, Non-Steroidal Anti-Inflammatory Drugs, and Cyclooxygenase-2 Selective Nonsteroidal Anti-Inflammatory Drugs Among US Primary Care Providers. *Aliment Pharmacol Ther.* 2008;28(10):1249-58.
188. Chan FK, Abraham NS, Scheiman JM, Laine L; First International Working Party on Gastrointestinal and Cardiovascular Effects of Non-Steroidal Anti-inflammatory Drugs and Anti-Platelet Agents. Management of Patients on Non-Steroidal Anti-Inflammatory Drugs: A Clinical Practice Recommendation from the First International Working Party on Gastrointestinal and Cardiovascular Effects of Non-Steroidal Anti-inflammatory Drugs and Anti-Platelet Agents. *Am J Gastroenterol.* 2008;103(11):2908-18.
189. Fendrick AM, Greenberg BP. A Review of the Benefits and Risks of Non-Steroidal Anti-Inflammatory Drugs in the Management of Mild-to-Moderate Osteoarthritis. *Osteopath Med Prim Care.* 2009;3(1):1.
190. Spaulding A, Fendrick AM, Herman WH, Stevenson JG, Smith DG, Chernew ME, Parsons DM, Bruhnens K, Rosen AB. A Controlled Trial of Value-Based Insurance Design - The MHealthy: Focus on Diabetes (FOD) Trial. *Implement Sci.* 2009; 4:19.
191. Dalton VK, Harris LH, Clark SJ, Cohn L, Guire K, Fendrick AM. Treatment Patterns for Early Pregnancy Failure in Michigan. *J Womens Health (Larchmt).* 2009;18(6):787-93.
192. Fendrick AM, Chernew ME. Value Based Insurance Design: Maintaining a Focus on Health in an Era of Cost Containment. *Am J Manag Care.* 2009;15(6):338-43.
193. Landsman PB, Smith DG, Fendrick AM. Healthcare Utilization in Community-Acquired Pneumonia Episodes of Care: A Comparison Across the Continuum of Managed Care. *Med Care.* 2009;47(10):1084-90.
194. Fendrick AM, Chernew ME, Levi GW. Value-Based Insurance Design: Embracing Value Over Cost Alone. *Am J Manag Care.* 2009;15(10 Suppl):S277-83.
195. Chernew M, Gibson TB, Fendrick AM. Trends in Patient Cost Sharing for Clinical Services Used as Quality Indicators. *J Gen Intern Med.* 2010;25(3):243-8.
196. Chernew ME, Juster IA, Shah MR, Wegh A, Rosenberg SN, Rosen AB, Sokol MC, Yu-Isenberg K, Fendrick AM. Evidence that Value-based Insurance Can Be Effective. *Health Aff.* 2010;29(3):530-6.
197. Kerber KA, Fendrick AM. The Evidence Base for the Evaluation and Management of Dizziness. *J Eval Clin Pract.* 2010;16(1):186.
198. Dalton VK, Harris LH, Gold KJ, Kane-Low L, Schulkin J, Guire K, Fendrick AM. Provider Knowledge, Attitudes, and Treatment Preferences for Early Pregnancy Failure. *Am J Obstet Gynecol.* 2010;202(6):531.
199. Kerber KA, Schweigler L, West BT, Fendrick AM, Morgenstern LB. Value of CT scans in ED dizziness visits: Analysis from a nationally representative sample. *Am J Emerg Med.* 2010;28(9):1030-6.
200. Fendrick AM, Smith DG, Chernew ME. Applying Value-Based Insurance Design to Low-Value Health Services. *Health Aff (Millwood).* 2010;29(11):2017-21.
201. Manson SC, Benedict A, Pan F, Wittrup-Jensen KU, Fendrick AM. Potential Economic Impact of Increasing Low Dose Aspirin Usage on CVD in the US. *Curr Med Res Opin.* 2010;26(10):2365-73.

202. Saini SD, Fendrick AM. Value-Based Insurance Design: Implications for Gastroenterology. *Clin Gastroenterol Hepatol.* 2010;8(9):767-9.
203. Fendrick AM. A Pharmacoeconomic Perspective on Stroke Prevention in Atrial Fibrillation. *Am J Manag Care.* 2010;16(10 Suppl):S284-90.
204. Fendrick AM. Value-Based Insurance Design for Diabetes Mellitus: Approaches to Optimal Pharmacoeconomic Implementation. *Am J Manag Care.* 2010;16(11 Suppl):S314-22.
205. Earnshaw SR, Scheiman J, Fendrick AM, McDade C, Pignone M. Cost-Utility of Aspirin and Proton Pump Inhibitors for Primary Prevention. *Arch Intern Med.* 2011;171(3):218.
206. Dalton VK, Harris LH, Bell JD, Schulkin J, Steinauer J, Zochowski M, Fendrick AM. Treatment of Early Pregnancy Failure: Does Induced Abortion Training Affect Later Practices? *Am J Obstet Gynecol.* 2011;204(6):493.
207. de Souza JA, Polite BN, Manning WG, Fendrick AM, Ratain MJ. Value-Based Insurance Design in Oncology. *Lancet Oncol.* 2011;12(4):321.
208. Cox JV, Fendrick AM. Developing Dialogue in Healthcare. *Am J Manag Care.* 2011;17 Suppl 5 SP19. Published simultaneously in *J Oncol Pract.* 2011;7(3 Suppl):17s.
209. Kerber KA, Morgenstern LB, Meurer WJ, McLaughlin T, Hall PA, Forman J, Fendrick AM, Newman-Toker DE. Nystagmus Assessments Documented by Emergency Physicians in Acute Dizziness Presentations: a Target for Decision Support? *Acad Emerg Med.* 2011;18(6):619-26.
210. Saini SD, Fendrick AM, Scheiman JM. Cost-Effectiveness Analysis: Cardiovascular Benefits of Proton Pump Inhibitor Co-therapy in Patients Using Aspirin for Secondary Prevention. *Aliment Pharmacol Ther.* 2011;34(2):243-51.
211. Callaghan BC, Kerber K, Smith AL, Fendrick AM, Feldman EL. The Evaluation of Distal Symmetric Polyneuropathy: A Physician Survey of Clinical Practice. *Arch Neurol.* 2012;69(3):339-345.
212. Gibson TB, Landrum MB, Batata A, Fendrick AM, Wang S, Chernew ME. Regional Variation in Medication Adherence. *Forum Health Econ Pol.* 2011;14(2):1-22.
213. de Souza JA, Ratain MJ, Fendrick AM. Value-Based Insurance Design: Aligning Incentives, Benefits, and Evidence in Oncology. *J Natl Compr Canc Netw.* 2012;10(1):18-23.
214. Fendrick AM, Martin JJ, Weiss AE. Value-Based Insurance Design: More Health at Any Price. *Health Serv Res.* 2012;47(1 Pt 2):404-13.
215. Kerber KA, Burke JF, Skolarus LE, Callaghan BC, Fife TD, Baloh RW, Fendrick AM. A Prescription for the Epley Maneuver: <http://www.youtube.com/> *Neurol.* 2012;79(4):376- 380.
216. Frank MB, Fendrick AM, He Y, Zbrozek A, Holtz N, Leung S, Chernew ME. The Effect of a Large Regional Health Plan's Value-Based Insurance Design Program on Statin Use. *Med Care.* 2012;50(11):934-9.
217. Stecker EC, Riles EM, Fendrick AM. Value-Based Insurance Design in Cardiology: Using "Clinical Nuance" to Improve Quality of Care and Contain Costs. *J Am Coll Cardiol.* 2012;60(18):1825-1827.
218. Zhang YT, Baik SH, Fendrick AM, Baicker K. Comparing Local and Regional Variation in Health Care Spending. *NEJM.* 2012;367(18):1724-31.
219. Gibson TB, Fendrick AM, Gatwood J, Chernew ME. Gaps in Treatment, Treatment Resumption and Cost-sharing. *Am J Pharm Benefits.* 2012;4(6):e159-e165.
220. Kerber KA, Burke JF, Skolarus LE, Meurer WJ, Callaghan BC, Brown DL, Lisabeth LD, McLaughlin TJ, Fendrick AM, Morgenstern LB. Use of BPPV Processes in Emergency Department Dizziness Presentations: A Population-Based Study. *Otolaryngol Head Neck Surg.* 2013;148(3):425-30.
221. Dusetzina SB, Dalton VK, Chernew ME, Pace L, Bowden G, Fendrick AM. Cost of Contraceptive Methods to Privately Insured Women in the U.S. *Womens Health Issues.* 2013;23(2):e69-71.

222. Zhang Y, Wu SH, Fendrick AM, Baicker K. Geographic Variation in Medication Adherence and Medical Spending Among Medicare Beneficiaries with Heart Failure. *JAMA Intern Med* 2013;173(6):468-70.
223. Chernew ME, McKellar R, Aubry W, Beck R, Benner J, Berger JE, Fendrick AM, Forma F, Goldman D, Harmel AP, Killion R, Lakdawalla D, Owens DK, Stahl J. Comparative Effectiveness Research and Formulary Placement: The Case of Diabetes. *Am J Manag Care*. 2013;19(2):93-96.
224. Song Z, Fendrick AM, Safran DG, Landon BE, Chernew ME. Global Budgets and Technology-Intensive Medical Services. *Healthcare: J Delivery Sci Innov*. 2013;1(1):15-21.
225. Northouse L, Mood D, Schafenacker A, Kalemkerian G, Zalupski M, LoRusso P, Hayes D, Hussain M, Ruckdeschel J, Fendrick AM, Trask P, Ronis D, Kershaw T. Randomized Clinical Trial of a Brief and Extensive Dyadic Intervention for Advanced Cancer Patients and Their Family Caregivers. *Psycho-Oncology*. 2013;22(3):555-63.
226. Xu X, Spurr SJ, Nan B, Fendrick AM. The Effects of Medical Malpractice Liability on Rate of Referrals Receive by Specialist Physicians. *Health Econ Policy Law*. 2013;8(4):453-75.
227. Wargo JJ, Northouse LL, Schafenacker AM, Fendrick AM. Lack of Discontinuation of Statin Therapy After Diagnosis of End-Stage Cancer. *Contemporary Onc*. 2013;5(1):15-17.
228. Fendrick AM, Zank D. Value-Based Insurance Design: Aligning Incentives and Evidence in Pulmonary Medicine. *Chest*. 2013;144(5):1712-6.
229. Pace LE, Dusetzina SB, Fendrick AM, Keating NL, Dalton VK. The Impact of Out-of-Pocket Costs on Use of Intrauterine Contraception Among Women with Employer-Sponsored Insurance. *Med Care*. 2013;51(11):959-96.
230. Sharp AL, Song Z, Chernew ME, Safran DG, Chernew ME, Fendrick AM. The Effect of Bundled Payment on Emergency Department Use: Alternative Quality Contract Effects after Year One. *Acad Emerg Med*. 2013;20(9):961-964.
231. Riles EM, Jain AV, Fendrick AM. Medication Adherence and Heart Failure. *Current Curr Cardiol Rep*. 2014;16(3):458.
232. McKellar MR, Chernew ME, Fendrick AM. The Economics of Resistant Pathogens and Antibiotic Innovation. *Am J Manag Care*. 2014;20(3):193-197.
233. Hall K, Fendrick AM, Zochowski M, Dalton VK. Women's Health and the Affordable Care Act: High Hopes Versus Harsh Realities? *Am J Pub Health*. 2014;104(8):10-13.
234. Gibson TB, Ehrlich ED, Graff J, Dubois R, Chernew ME, Farr AM, Chernew ME, Fendrick AM. Real World Impact of Comparative Effectiveness Research (CER) Findings on Clinical Practice. *Am J Manag Care*. 2014;20(6):e208-e220.
235. Buxbaum JD, de Souza J, Fendrick AM. Using Clinically Nuanced Cost-Sharing to Enhance Consumer Access to Specialty Medications. *Am J Manag Care*. 2014;20(6):e242-e244.
236. McKellar MR, Fendrick AM. Innovation of Novel Antibiotics: An Economic Perspective. *Clin Infect Dis*. 2014;59(3):s104-107.
237. Gatwood J, Gibson TB, Chernew ME, Farr AM, Vogtmann E, Fendrick AM. Price Elasticity and Medication Use: Cost-sharing Across Multiple Clinical Conditions. *J Manag Care Pharm*. 2014;20(11):1102-07.
238. Kerber KA, Zahuranec DB, Brown DL, Meurer WJ, Burke JF, Smith MA, Lisabeth LD, Fendrick AM, McLaughlin T, Morgenstern LB. Stroke Risk after ED Dizziness Presentations: A Population-Based Study. *Ann Neurol*. 2014;75(6):899-907.
239. Oster G, Fendrick AM. Skin in the Game - or Simply Getting Skinned? The Problem with "Non-Preferred" Generics. *Am J Manag Care*. 2014;20(9):693-695.
240. Elliott DJ, Sonnad SS; Xu X; Anthony K, Robinson EJ, Aguiar RT, Barron J, Stillman P, Fendrick AM. Factors Associated with Employee Participation in a Value-Based Insurance Design Initiative. *Am J Pharm Benefits*. 2013;5(6):272-278.

241. Afendulis CC, Fendrick AM, Song Z, Landon BE, Safran DG, Mechanic RE, Chernew ME. The Impact of Global Budgets on Pharmaceutical Spending and Utilization: Early Experience from the Alternative Quality Contract. *Inquiry*. 2014;51:1-7.
242. Dalton VK, Liang A, Hutton DW, Zochowski M, Fendrick AM. Beyond Usual Care: The Economic Consequences of Expanding Treatment Options in Early Pregnancy Loss. *Am J Obstet Gynecol*. 2015;212(2):177e1-6.
243. Gibson TB, Maclean JR, Chernew ME, Baigel C, Fendrick AM. Value-Based Insurance Design: Benefits beyond Cost and Utilization. *Am J Manag Care*. 2015;21(1):32-35.
244. Martinez KA, Friese C, Kershaw T, Given CW, Fendrick AM, Northouse L. Effect of a Nurse-Led Psychoeducational Intervention on Healthcare Service Utilization Among Adults with Advanced Cancer. *Oncol Nurs Forum*. 2015;42(4):e310-8. DOI: 10.1188/15.ONF.E310-E318.
245. Stecker EC, Ayanian, JZ, Fendrick AM. Value-Based Insurance Design: Aligning Incentives to Improve Cardiovascular Health. *Circulation*. 2015;132(16):1580-1585.
246. Kerber KA, Meurer W, Brown D, Burke J, Hofer T, Tsodikov A, Hoeffner E, Fendrick AM, Adelman E, Morgenstern L. Stroke Risk Stratification in Acute Dizziness Presentations: A Prospective Imaging-Based Study. *Neurol*. 2015;85(21):1869-1878.
247. Chernew ME, Golden WE, Mathis CH, Fendrick AM, Motley MW, Thompson JW. The Arkansas Payment Improvement Initiative: Early Perceptions of Multi-Payer Reform in a Fragmented Provider Landscape. *Am J Accountable Care*. 2015;6(15):34-38.
248. Hirth R, Cliff BQ, Gibson TB, McKellar MR, Fendrick, AM. Connecticut's Value-Based Insurance Plan Increased the Use of Targeted Services and Medication Adherence. *Health Aff*. 2016;35(4):637-46.
249. McKellar MR, Landrum MB, Gibson TB, Landon BE, Fendrick AM, Chernew ME. Geographic Variation in Quality of Care for Commercially Insured Patients. *Health Serv Res*. 2016;315(17):1874-81.
250. Clarke JL, Skoufalos A, Medalia A, Fendrick AM. Improving Health Outcomes for Patients with Depression: A Population Health Imperative. Report on an Expert Panel Meeting. *Popul Health Manag*. 2016;19 Suppl 2:S1-S12.
251. Cotton P, Newhouse JP, Volpp KG, Fendrick AM, Oesterle SL, Oungpasuk P, Aggarwal R, Wilensky G, Sebelius K. Medicare Advantage: Issues, Insights, and Implications for the Future. *Popul Health Manag*. 2016;19(S3):S1-S8.
252. Chernew ME, Fendrick AM. Improving Benefit Design to Promote Effective, Efficient, and Affordable Care. *JAMA*. 2016;316(16):1651-1652.
253. Fendrick AM, Chernew ME. Precision Benefit Design – Using “Smarter” Deductibles to Better Engage Consumers and Mitigate Cost-Related Nonadherence. *JAMA Intern Med*. 2017;177(3):368-370
254. Kullgren J, Segel JE, Peterson T, Fendrick AM, Singh S. Availability and Variation of Publicly Reported Prescription Drug Prices. *Am J Manag Care*. 2017;23(7):444-448.
255. Mafi JN, Russell K, Bortz B, Hazel W, Dachary M, Fendrick AM. Low-Cost, High-Volume Health Services Contribute the Most to Unnecessary Health Spending. *Health Aff*. 2017;36(10):1701-1704.
256. Kullgren J, Cliff BQ, Krenz C, West B, Levy H, Fendrick AM, Winkelman T, So J, Fagerlin A. Consumer Behaviors Among Americans in High-Deductible Health Plans. *JAMA Intern Med*. 2018;178(3):424-426. DOI: 10.1001/jamainternmed.2017.6622.
257. Buxbaum JD, Chernew ME, Bonafede M, Vlahiotis A, Walter D, Mucha L, Fendrick AM. Cost-Sharing and Branded Antidepressant Initiation among Patients Treated with Generics. *Am J Manag Care*. 2018;24(4):180-186.

258. Dalton VK, Carlos R, Moniz M, Kolonic G, Kamdar NS, Kobernik EK, Fendrick AM. The Impact of Cost Sharing on Women's Use of Annual Examinations and Effective Contraception. *Am J Obstet Gynecol.* 2018;219(1):93. e1-93.e13. DOI: 10.1016/j.ajog.2018.04.051.
259. Agarwal R, Gupta A, Fendrick AM. Value-Based Insurance Design Improves Medication Adherence Without an Increase in Total Health Care Costs. *Health Aff.* 2018;37(7):1057–1064.
260. Fendrick AM, He X, Liu D, Buxbaum JD, Mitchell BD. Glucagon Prescriptions for Diabetes Patients After Emergency Department Visits for Hypoglycemia. *Endocr Pract.* 2018;24(10):861- 866.
261. Carroll C, Chernew ME, Fendrick AM, Thompson J, Rose S. Effects of Episode-Based Payment on Health Care Spending and Utilization: Evidence from Perinatal Care in Arkansas. *J Health Econ.* 2018; 61:47-62. DOI: 10.1016/j.jhealeco.2018.06.010.
262. Tao Z, Li Y, Stemkowski S, Johnson KD, Acosta CJ, Zhang D, Fendrick AM. Impact of Patient Cost on Herpes Zoster Vaccine Utilization: An Observational Study in a Medicare Managed Care Population. *Vaccines.* 2018;6(4). pii: E78. DOI: 10.3390/vaccines6040078.
263. Anupam JB, Chou J, Yoon L, Aubry WM, Berger J, Burton W, Fendrick AM, Fick D, Franklin D, Killion R, Lakdawalla D, Neumann P, Patel K, Yee J, Sakurada B, Yu-Isenberg K. Understanding and Improving Value Frameworks with Real-World Patient Outcomes. *Am J Manag Care.* 2018;24(11):506-509.
264. Platt K, Thompson AN, Lin P, Banerjee T, Linden A, Fendrick AM. Utilization of Self-Monitoring of Blood Glucose in Individuals with Type 2 Diabetes Not Using Insulin. *JAMA Intern Med.* 2019;179(2):269-272. DOI: 10.1001/jamainternmed.2018.5700.
265. Kim D, Cohen J, Wong J, Mohit B, Fendrick AM, Kent D, Neumann P. Targeted Incentive Programs for Lung Cancer Screening Can Improve Population Health and Economic Efficiency. *Health Aff.* 2019;38(1):60-67. DOI: 10.1377/hlthaff.2018.05148.
266. Cliff EQ, Krenz C, West BT, Levy H, Fendrick AM, Winkelman T, So J, Fagerlin A, Kullgren JT. Attitudes about Value-Conscious Consumer Strategies among Americans in High-Deductible Health Plans. *Med Care.* 2019;57(3):187-193. DOI: 10.1097/MLR.0000000000001056.
267. Kullgren JT, Cliff EQ, Krenz C, Levy H, West BT, Fendrick AM, So J, Fagerlin A. A Survey of Americans with High-Deductible Health Plans Identifies Opportunities to Enhance Consumer Behaviors. *Health Aff.* 2019;38(3):416–424. DOI: 10.1377/hlthaff.2018.05018.
268. Cliff EQ, Hirth R, Fendrick AM. Spillover Effects from a Consumer-Based Intervention to Increase High-Value Preventive Care. *Health Aff.* 2019;38(3):448–455. DOI: 10.1377/hlthaff.2018.05015.
269. Carlos R, Fendrick AM, Kolenic G, Kamdar N, Kobernik E, Bell S, Dalton VK. Breast Screening Utilization and Cost-Sharing Among Employed Insured Women After the Affordable Care Act. *J Am Coll Radiol.* 2019;16(6):788-796. DOI: 10.1016/j.jacr.2019.01.028.
270. Fazeli Dehkordy S, Fendrick AM, Bell S, Kamdar N, Kobernik E, Dalton VK, Carlos RC. Breast Screening Utilization and Cost-Sharing Among Employed Insured Women Following the Affordable Care Act: Impact of Race and Income. *J Womens Health.* 2019;28(11):1529-1537. DOI: 10.1089/jwh.2018.7403.
271. Brixner D, Rubin DT, Mease P, Mittal M, Liu H, Davis M, Ganguli A, Fendrick AM. Patient Support Program Increased Medication Adherence with Lower Total Healthcare Costs Despite Increased Drug Spending. *J Manag Care Spec Pharm.* 2019;25(7):770-779. DOI: 10.18553/jmcp.2019.18443.

272. Brixner D, Mittal M, Rubin DT, Mease P, Liu HH, Davis M, Ganguli A, Fendrick AM. Participation in an Innovative Patient Support Program Reduces Prescription Abandonment for Adalimumab-Treated Patients in a Commercial Population. *Patient Prefer Adherence*. 2019;(13):1545-1556. DOI: 10.2147/PPA.S215037.
273. Schwartz E, Ruff A, Kinning M, Fendrick AM. Ease of Ordering High and Low Value Clinical Services in Electronic Medical Records. *Am J Manag Care*. 2019;25(10):517-520.
274. Ruff AL, Seiler K, Brady P, Fendrick AM. Naloxone Fill Rates After Opioid Overdose. *J Addict Med Ther Sci*. 2019;5(1):001-002. DOI: 10.17352/2455-3484.000027.
275. Fendrick AM, Buxbaum JD, Tang Y, Vlahiotis A, McMorro D, Rajpathak S, Chernew ME. Association Between Switching to a High-Deductible Health Plan and Discontinuation of Type 2 Diabetes Treatment. *JAMA Netw Open*. 2019;2(11):e1914372. DOI: 10.1001/jamanetworkopen.2019.14372.
276. Moniz M, Soliman A, Kolenic G, Tilea A, Fendrick AM, Bell S, Dalton VK. Cost-Sharing and Utilization of Postpartum Intrauterine Devices and Contraceptive Implants Among Commercially Insured Women. *Womens Health Issues*. 2019;29(6):465-470. DOI: 10.1016/j.whi.2019.07.006.
277. Chen JL, Chernew ME, Fendrick AM, Thompson J, Rose S. The Impact of Episode-based Payment Initiative by Commercial Payers in Arkansas on Procedure Volume: An Observational Study. *J Gen Intern Med*. 2020;(35):578–585. DOI:10.1007/s11606-019-05318-7.
278. Moniz MH, Fendrick AM, Kolenic GE, Tilea A, Admon, LK, Dalton VK. Out-of-Pocket Spending for Maternity Care Among Women with Employer-Based Insurance, 2008-2015. *Health Aff*. 2020;39(1):18–23. DOI: 10.1377/hlthaff.2019.00296.
279. Myers CD, Kieffer E, Fendrick AM, Kim HM, Salman C, Calhoun K, LaHahnn L, Ledon C, Danis M, Rowe Z, Goold SD. How Would Low-Income Communities Prioritize Medicaid Spending? *J Health Polit Policy Law*. 2020;45(3):373-418. DOI: 10.1215/03616878-8161024.
280. Peahl AF, Gourevitch RA, Luo EM, Fryer KE, Moniz MH, Dalton VK, Fendrick AM, Shah N. Right-Sizing Prenatal Care: How Tailoring Care to Patients' Needs Can Improve Maternity Care Value. *Obstet Gynecol*. 2020;135(5):1027-1037. DOI: 10.1097/AOG.0000000000003820.
281. Yabroff KR, Valdez S, Jacobson M, Han X, Fendrick AM. The Changing Health Insurance Coverage Landscape in the United States. *Am Soc Clin Oncol Educ Book*. 2020;40:e264-e274. DOI:10.1200/EDBK_279951K.
282. Kirsch M, Montgomery J, Hu HM, Englesbe M, Hallstrom B, Brummett C, Fendrick AM, Waljee J. Association Between Insurance Cost-Sharing Subsidy and Postoperative Opioid Prescription Refills Among Medicare Patients. *Surgery*. 2020;2:244-252. DOI: 10.1016/j.surg.2020.04.013.
283. Kim DD, Ollendorf DA, Neumann PJ, Fendrick AM. Crisis Into Opportunity: Can COVID-19 Help Set a Path to Improved Health Care Efficiency? *AJMC*. 2020;26(9):369-70.
284. Seymour EK, deSouza JA, Fendrick AM. Incorporating Value-Based Care into Oncology. *The Cancer Journal*. 2020;26(4):311-322. DOI: 10.1097/PPO.0000000000000459.
285. Kullgren JT, Cliff BQ, Krenz C, Levy H, West B, Fendrick AM, Fagerlin A. Use of Health Savings Accounts Among US Adults Enrolled in High-Deductible Health Plans. *JAMA Network Open*. 2020;3(7):e2011014. DOI:10.1001/jamanetworkopen.2020.11014.
286. Fendrick AM. The Need to Expand Coverage and Enhance Access to Essential Services on a Predeductible Basis Following COVID-19. *JAMA Network Open*. 2020;3(7):e209456. DOI:10.1001/jamanetworkopen.2020.9456.
287. Bone RH, Cross JD, Dwyer AJ, Fox JL, Hyams DM, Hassmiller Lich K, Mackey TA, Miller RM, Fendrick AM. A Path to Improve Colorectal Cancer Screening Outcomes: Faculty Roundtable Evaluation of Cost-Effectiveness and Utility. *AJMC*. 2020;26:S123-S143. DOI:10.37765.

288. Reid RO, Mafi JN, Baseman LH, Fendrick AM, Damberg CL. Waste in the Medicare Program: A National Cross-sectional Analysis of 2017 Low-Value Service Use and Spending. [published online ahead of print, 2020 Jul 29]. *J Gen Intern Med.* 2020;10.1007/s11606-020-06061-0. doi:10.1007/s11606-020-06061-0.
289. Buxbaum JD, Chernew ME, Fendrick AM, Cutler DM. Contribution of Public Health, Pharmaceuticals, and Other Medical Care to US Life Expectancy Changes, 1990-2015. *Health Aff.* 2020 Sep;39(9):1546-1556. <https://doi.org/10.1377/hlthaff.2020.00284>.
290. Dalton VK, Moniz MH, Bailey M, Admon LK, Kolenic GE, Tilea A, Fendrick AM. Trends in Birth Rates After Elimination of Cost Sharing for Contraception by the Affordable Care Act. *JAMA Network Open.* 2020;3(11):e2024398. doi:10.1001/jamanetworkopen.2020.24398.
291. Piscitello A, Saoud L, Matney M, Borah BJ, Fendrick AM, Hassmiller Lich K, Rinde H, Limburg P. Description and Validation of the Colorectal Cancer and Adenoma Incidence & Mortality (CRC-AIM) Microsimulation Model. *bioRxiv.* 2020. doi: <https://doi.org/10.1101/2020.03.02.966838>.
292. Moniz MH, Peahl AF, Fendrick AM, Kolenic GE, Tilea A, Wetmore M, Dalton V. Cost-Sharing, Postpartum Contraceptive Use, and Short-Interval Pregnancy Rates Among Commercially Insured Women. *Am J Obstet Gynecol.* 2021;224(3):282.E1-282.E17. DOI:<https://doi.org/10.1016/j.ajog.2020.08.109>.
293. Scheiman JM, Fendrick AM, Nuliyal U, Ryan AM, Chhabra KR. Surprise Billing for Colonoscopy: The Scope of the Problem. *Ann Int Med.* 2021;174(3):426-428. DOI:10.7326/M20-2928.
294. Fisher DA, Saoud L, Lich KH, Fendrick AM, Ozbay AB, Borah BJ, Matney M, Parton M, Limburg PJ. Impact of Screening and Follow-Up Colonoscopy Adenoma Sensitivity on Colorectal Cancer Screening Outcomes in the CRC-AIM Microsimulation Model. *Cancer Epidemiology Biomarker Prevention.* *Cancer Medicine.* 2021;10(8):2855-2864. <https://doi.org/10.1002/cam4.3662>.
295. Piscitello A, Saoud L, Fendrick AM, Borah BJ, Hassmiller Lich K, Matney, Ozbay AB, Parton M, Limburg PJ. Estimating the Impact of Differential Adherence on the Comparative Effectiveness of Stool-Based Colorectal Cancer Screening Using the CRC-AIM Microsimulation Model. *PLOS ONE.* 15(12):e0244431. <https://doi.org/10.1371/journal.pone.0244431>.
296. Kullgren JT, Fendrick AM. The Price Will Be Right – How to Help Patients and Providers Benefit from the New CMS Transparency Rule. *JAMA Health Forum.* 2021; 2(2):e210102. doi: 10.1001/jamahealthforum.2021.0102.
297. Mafi JM, Reid RO, Baseman, LH, Hickey S, Totten M, Agniel D, Fendrick AM, Sarkisian C, Damberg CL. Trends in Low-Value Health Service Utilization and Spending in the U.S. Medicare Fee-For-Service Program, 2014-2017. *JAMA Network Open.* 2021; 4(2):e2037328. doi:10.1001/jamanetworkopen.2020.37328.
298. Oronce CI, Fendrick AM, Ladapo J, Sarkisian C, Mafi JM. The Utilization and Costs of Grade D USPSTF Services in Medicare, 2007-2016. *J Gen Intern Med.* E-pub ahead of print. 2021 Apr. doi:10.1007/s11606-021-06784-8
299. Chandrashekar P, Fendrick AM, Ganguli I. Stopping the Flood: Reducing Harmful Cascades of Care. *AJMC.* 2021;27(5):178-180. <https://doi.org/10.37765/ajmc.2021.88630>
300. Fendrick AM, Macaulay D, Goldschmidt D, Liu, H, Brixner D, Tauseef Ali T, Mittal M. Higher Medication Adherence and Lower Opioid Use among Individuals with Autoimmune Disease Enrolled in an Adalimumab Patient Support Program in the United States. *Rheumatology and Therapy.* 2021;(8):889-901. <https://doi.org/10.1007/s40744-021-00309-9>

301. Fisher DA, Karlitz JJ, Jeyakumar S, Smith N, Limburg P, Lieberman D, Fendrick AM. Real-world cost-effectiveness of stool-based colorectal cancer screening in a Medicare population. *Journal of Medical Economics*. 2021;24(1):654-664. <https://doi.org/10.1080/13696998.2021.1922240>
302. Fendrick AM, Fisher DA, Saoud L, Ozbay AB, Karlitz JJ, Limburg PJ. Impact of Patient Adherence to Stool-Based Colorectal Cancer Screening and Colonoscopy Following a Positive Test on Clinical Outcomes. *Cancer Prevention Research*. E-pub ahead of print. 2021. doi: 10.1158/1940-6207.CAPR-21-0075
303. Agochukwu-Mmonu N, Fendrick AM. The Economics of Viagra Revisited: The Price is Right. *Urology*. E-pub ahead of print. 2021. doi: 10.1016/j.urology.2021.05.037
304. Chua KP, Fendrick AM, Conti RM, Moniz MH. Out-of-Pocket Spending for Deliveries and Newborn Hospitalizations Among the Privately Insured. *Pediatrics*. 2021;148(1):e2021050552. DOI: 10.1542/peds.2021-050552
305. Norris HC, Richardson HM, Benoit MC, Shrosbree B, Smith JE, Fendrick AM. Utilization Impact of Cost-Sharing Elimination for Preventive Care Services: A Rapid Review. *Medical Care Research and Review*. E-pub ahead of print. 2021. doi.org/10.1177/10775587211027372
306. Chua KP, Fendrick AM, Conti RM, Moniz MH. Prevalence and Magnitude of Potential Surprise Bills for Childbirth. *JAMA Health Forum*. 2021;e211460. doi:10.1001/jamahealthforum.2021.1460
307. Fendrick AM, Brixner D, Rubin DT, Mease P, Liu H, Davis M, Mittal M. Sustained long-term benefits of patient support program participation in immune mediated diseases: improved medication-taking behavior and lower risk of a hospital visit. *Journal of Managed Care & Specialty Pharmacy*. 2021 Aug;27(8);1086-1095. <https://doi.org/10.18553/jmcp.2021.20560>.

Non Peer-Reviewed Publications

1. Fendrick, AM. The 1700-Year-Old Mummy and Its *H. pylori* Antigens. *Practical Gastroenterol*. 1998;35-40.
2. Fendrick, AM. Who Should Be Treated for *H. pylori* Infection? *Hippocrates*. 2000;14(4):29-32.
3. Fendrick AM. Access to Innovative Treatment of Erectile Dysfunction: Clinical, Economic and Quality of Life Considerations. *Am J Manag Care*. 2000;6(12Suppl):S632-S638.
4. Fendrick AM, Berardi RR. Therapeutic Options for GERD: What's the Correct Approach? *J Am Pharm Assoc*. 2000;40(5):S52-S53.
5. Shehab TJ, Fendrick AM. Educational Opportunities Persist for Primary Care Physicians to Improve Quality of Care for Individuals with Hepatitis C Virus Infection. *Advances in Hepatitis C*. 2000;1(4):11-12.
6. Saint S, Fendrick AM. Economic Evaluation: A Brief Overview. *Clinical Researcher*. 2001;2:36-39.
7. Fendrick AM, Scheiman JM. *Helicobacter pylori* and NSAID Gastropathy: An Ambiguous Association. *Curr Rheumatol Rep*. 2001;3(2):107-111.
8. Scheiman JM, Fendrick AM. *Helicobacter pylori* Eradication for Individuals on Chronic NSAID Therapy: Should We Kill the Bug if You Need the Drug? *Pract Gastroenterol*, 2001;25(5):12- 24.
9. Fendrick AM. The Increasing Burden of Care: Alzheimer's Disease in Perspective. *Patient-Care Strategies for the Management of Alzheimer's Disease*. 2001.
10. McKinnon P, Fendrick AM, Zinner SH. Challenges in the Diagnosis and Management of Respiratory Tract Infections. *U.S. Pharmacist*. 2001;26(7):73-82.
11. Fendrick AM, Langa KM. The Far-Reaching Effects of Alzheimer's Disease. *Elder Care*. 2002;2(4):1-4.

12. Fendrick AM, Garabedian-Ruffalo SM. Management Strategies for Individuals Who Take NSAIDs and Require Aspirin to Reduce Cardiovascular Risk. *Scope*. 2003;5:10-14
13. Fendrick AM. State-Of-The-Art Management of Mild-To-Moderate Pain from Adolescence Through Old Age-Proceedings Highlights. *Clinical Courier*. 2003;22(4):1-11.
14. Fendrick AM. Pharmacist Guide to Patients' Frequently Asked Questions. Contributor. 2004.
15. Fendrick AM. A Cost-Effective Disease Management Approach to Minimizing NSAID-Related GI Mucosal Injury. *J Manag Care Med*. 2004;7(3):18-22.
16. Fendrick AM, Bernstein SJ, Scheiman JM. Prevention of NSAID Induced Ulcers in the Elderly. *Geriatrics*. 2005;Suppl3-12.
17. Katz PO, Laine L, Chan FKL, Fendrick AM. NSAIDs, Coxibs, and Antiplatelet Agents: Balancing the Gastrointestinal and Cardiovascular Risks and Benefits. *Medscape Clinical Update*. 2006. <http://www.medscape.com/viewprogram/5003>.
18. Fendrick AM, Goldhaber S, Scheiman JM, Solomon SD. Weighing the Risks and Benefits of Coxibs, NSAIDs and Antiplatelet Therapy: Where the Data Lead. *Medscape Clinical Update*. 2006. <http://www.medscape.com/viewprogram/5094>.
19. Fendrick AM. Value-Based Insurance Design Landscape Digest. White Paper. National Pharmaceutical Council. 2009. http://vbidcenter.org/wp-content/uploads/2014/08/NPC_VBIDreport_7-22-09.pdf
20. Chernew ME, Fendrick AM. Value Based Insurance Design: Restoring Health to The Health Care Cost Debate. American Society of Actuaries. 2009.
21. Fendrick AM, Sherman B, White D. Aligning Incentives and Systems, Promoting Synergy Between Value-Based Insurance Design and the Patient Centered Medical Home. Patient-Centered Primary Care Collaborative. White Paper. 2010. <https://vbidcenter.org/wp-content/uploads/2014/10/Aligning-Incentives-and-Innovations-promoting-synergies-btw-V-BID-PCMHs.pdf>
22. Fendrick AM, Jinnett K, Parry T. Synergies at Work: Realizing the Full Value of Health Investments. National Pharmaceutical Council. White Paper. 2011. https://www.npcnow.org/system/files/research/download/synergies_at_work_finalpaper.pdf
23. Gibson TB, Chernew ME, Fendrick AM. Cost-Sharing and Productivity. NBER. <http://www.nber.org/papers/w18402>
24. Fendrick AM, Sonnad SS. Value-Based Insurance Design for Diagnostics, Devices, and Procedures: A Novel Approach to Better Recognize the Effectiveness and Value of Medical Technology. Institute for Health Technology Studies. White Paper. 2012. <https://vbidcenter.org/wp-content/uploads/2014/08/V-BID-and-Devices-InHealth.pdf>
25. Fendrick AM, Ayanian JZ. Smarter Consumer Cost Sharing Using Clinical Nuance. *Harvard Business Review*. Blog Post. 2013. <https://hbr.org/2013/11/smarter-consumer-cost-sharing-using-clinical-nuance>
26. Fendrick AM, Buxbaum JD, Westrich K. Supporting Consumer Access to Specialty Medications Through Value-Based Insurance Design. White Paper. 2014. https://www.npcnow.org/system/files/research/download/2014-vbid-specialty-medications-npc-final-web_0.pdf
27. Patel K, Cliff BQ, Fendrick AM. Clinical Nuance: Benefit Design Meets Behavioral Economics. *Health Affairs*. Blog Post. 2014. <https://www.healthaffairs.org/doi/10.1377/hblog20140403.038296/full/>
28. Golden W, Thompson JW, Olson S, Hill R, Fendrick AM, Mathis C, Chernew M. Patient-Centered Medical Homes in Arkansas. *Health Affairs*. Blog Post. 2014. <https://www.healthaffairs.org/doi/10.1377/hblog20140520.039098/full/>

29. Golden W, Thompson JW, Motley M, Fendrick AM, Mathis C, Chernew M. Arkansas Payment Improvement Initiative: The First Year. Health Affairs. Blog Post. 2014. <https://www.healthaffairs.org/doi/10.1377/hblog20140825.040962/full/>
30. Thompson JW, Golden W, Motley M, Fendrick AM, Mathis C, Chernew M. Arkansas Payment Improvement Initiative: Private Carriers Participation in Design and Implementation. Health Affairs. Blog Post. 2014. <https://www.healthaffairs.org/doi/10.1377/hblog20141015.041812/full/>
31. Thompson JW, Golden W, Motley M, Fendrick AM, Mathis C, Chernew M. Arkansas Payment Improvement Initiative: Self-Insured Participation. Health Affairs. Blog Post. 2015. <https://www.healthaffairs.org/doi/10.1377/hblog20150107.043773/full/>
32. Chernew M, Schwartz JS, Fendrick AM. Reconciling Prevention and Value in the Health Care System. Health Affairs. Blog Post. 2015. <https://www.healthaffairs.org/doi/10.1377/hblog20150311.045208/full/>
33. Bacher G, Zina A, Fendrick AM. Beyond SGR: Aligning the Peanut Butter of Payment Reform with the Jelly of Consumer Engagement. Health Affairs. Blog Post. 2015. <https://www.healthaffairs.org/doi/10.1377/hblog20150422.047207/full/>
34. Golden W, Thompson JW, Motley M, Fendrick AM, Mathis C, Chernew M. Arkansas Payment Improvement Initiative: Expanding Episodes to Other Clinical Areas. Health Affairs. Blog Post. 2015. <https://www.healthaffairs.org/doi/10.1377/hblog20150519.047837/full/>
35. Fendrick AM. New Start New Jersey Podcast: Value-Based Insurance Design for Health. New Start New Jersey. Podcast. 2015. <https://www.nsnj.org/News/Podcasts/NSNJ-PODCAST-Value-Based-Insurance-Design-for-Heal>
36. Beaudin-Seiler B, Ciarametaro M, Dubois R, Lee J, Fendrick AM. Reducing Low-Value Care. Health Affairs. Blog Post. 2016. <https://www.healthaffairs.org/doi/10.1377/hblog20160920.056666/full/>
37. Lee J, Beaudin-Seiler B, Rhyan C, Fendrick AM. Rising Deductibles Are Not Yet a Financial Burden, but Early Evidence Shows an Impact on Access to Care. Altarum Institute. Blog Post. 2016.
38. Cliff B, Rozier M, Fendrick AM. Health Insurance Benefits Should Be Equitable, Not Necessarily Equal. Health Affairs. Blog Post. 2017. <https://www.healthaffairs.org/doi/10.1377/hblog20170522.060211/full/>
39. Buxbaum JD, Mafi JN, Fendrick AM. Tackling Low-Value Care: A New “Top Five” for Purchaser Action. Health Affairs. Blog Post. 2017. <https://www.healthaffairs.org/doi/10.1377/hblog20171117.664355/full/>
40. Mullangi S, Fendrick AM, Patel K. How to Persuade the Young and the Healthy to Sign Up for Health Insurance. Harvard Business Review. Blog Post. 2018. <https://hbr.org/2018/01/how-to-persuade-the-young-and-the-healthy-to-sign-up-for-health-insurance>
41. Lagisetty P, Bohnert A, Fendrick AM. Meeting the Opioid Challenge: Getting Naloxone to Those Who Need It Most. Health Affairs. Blog Post. 2018. <https://www.healthaffairs.org/doi/10.1377/hblog20180510.164285/full/>
42. Beaudin-Seiler B, Fendrick AM, Miller G. Optimizing Health Care Resource Allocation: The Research Consortium for Health Care Value Assessment. Health Affairs. Blog Post. 2018. DOI: [10.1377/hblog20180919.297087](https://doi.org/10.1377/hblog20180919.297087)
43. Fendrick AM. The Health Care Spending Disconnect: Star Wars vs. Flintstones. Morning Consult. 2018. <https://morningconsult.com/opinions/health-care-spending-disconnect-star-wars-vs-flintstones/>
44. Fendrick AM, Shope M. Precision Benefit Design: Using Clinical Benefit to Guide How Health Care Dollars Are Spent. J Clin Pathways. 2018;4(7):39-40. DOI: [10.25270/JCP.2018.09.00032](https://doi.org/10.25270/JCP.2018.09.00032).

45. Fendrick AM. A Patient-Centered Approach to Medicare Drug Reform. Real Clear Policy. 2018. https://www.realclearpolicy.com/articles/2018/11/08/a_patient-centered_approach_to_medicare_drug_reform_110901.html
46. Fendrick AM, Klein D. The Administration's Drug Rebate Proposal: An Opportunity to Put Patients First. Morning Consult. 2019. <https://morningconsult.com/opinions/administrations-drug-rebate-proposal-opportunity-put-patients-first/>
47. Fendrick AM. Opinion: Lower Out-of-Pocket Drug Costs for Needy. Detroit News. 2019. <https://www.detroitnews.com/story/opinion/2019/04/09/opinion-lower-out-pocket-drug-costs-needy/3403881002/>
48. Fendrick AM. Use Value-Based Insurance Design Principles to Lower the Soaring Cost of Prescription Drugs. Modern Healthcare. 2019. <https://www.modernhealthcare.com/opinion-editorial/commentary-use-value-based-insurance-design-principles-lower-drug-costs>
49. Fendrick AM, Chernew ME. The Good Stuff. Tradeoffs. Podcast. 2019. <https://tradeoffs.org/2019/12/11/season-1-ep-5/>
50. Beaudin-Seiler B, Rhyan C, Fendrick AM, Miller G. Estimating State-Level Prevalence of Low-Value Care Services Among the Privately Insured, 2015. Research Consortium for Health Care Value Assessment. 2020. https://www.hcvalueassessment.org/application/files/5615/8050/0804/Research_Consortium_Research_Brief_No._2.pdf
51. Fendrick AM. Value-Based Insurance Design. Illuminate HR Podcast. <https://podcasts.google.com/?feed=aHR0cHM6Ly9mZWVkcyc5idXp6c3Byb3V0LmNvbS8yNDgzNjkucnNz&episode=QnV6enNwcm91dC0yNDgzNjY2&hl=en&ved=2ahUKEwim9bjUtdnnAhVmRN8KHS-nDOcQjrkEegQIBxAM&ep=6>
52. Fendrick AM, Ricks DA. If You Have Insurance, You Shouldn't Be Paying Full Price for Insulin. Fortune. 2020. https://fortune.com/2020/01/29/insulin-chronic-disease-insurance-costs/?utm_source=website&utm_medium=press_release&utm_campaign=News_Fortune&utm_term=Fendrick_and_VBIDCenter
53. Rother J, Spangler K, Fendrick AM. Re-examining the Delivery of High-Value Care Through COVID-19. The Hill. 2020. <https://thehill.com/opinion/healthcare/502851-examining-the-delivery-of-high-value-care-through-covid-19>
54. Chernew ME, Fendrick AM, Armbruster K, de Brantes F. COVID-19 Effects On Care Volumes: What They Mean And How We Might Respond. Health Affairs. Blog Post. 2020. DOI: 10.1377/hblog20200702.788062
55. Fendrick AM. Reducing low-value services in the COVID-19 era: A conversation with Mark Fendrick. Podcast for Smarter Care Virginia. 2020. <https://podcasts.apple.com/us/podcast/smarter-care-connections/id1534625841?i=1000493682677>
56. Fendrick AM. Interview with Dr. Bob Goldberg. Patients Rising Podcast. 2020. https://patients-rising-podcast.simplecast.com/episodes/can-you-get-trumps-covid-care?utm_source=Twitter&utm_medium=Podcast_ep33&utm_campaign=Fendrick
57. Cutter C, Berlin NL, Fendrick AM. Establishing A Value-Based 'New Normal' For Telehealth. Health Affairs. Blog Post. 2020. DOI: 10.1377/hblog20201006.638022
58. Budros M, Chernew ME, Fendrick AM. Utilization and Spending on Low-Value Medical Care Across Four States. White Paper. 2020. <https://vbidhealth.com/docs/APCD-LVC-Final.pdf>
59. Fronstin PM, Roebuck MC, Buxbaum J, Fendrick AM. Do People Choose Wisely After Satisfying Health Plan Deductibles? Evidence From the Use of Low-Value Health Care Services. EBRI Issue Brief, no. 516. 2020. <https://www.ebri.org/publications/research-publications/issue-briefs/content/do-people-choose-wisely-after-satisfying-health-plan-deductibles-evidence-from-the-use-of-low-value-health-care-services>

60. Fendrick AM. Interview with Dr. Bob Goldberg. Patients Rising Podcast. 2020. <https://patientsrisingnow.org/episode-42-what-will-biden-do-for-patients/>
61. Ofman JJ, Fendrick AM, Raza A. Novel Multicancer Early Detection Technology—Potential Value to Employers and the Workforce. *AJMC*. 2020;26(10):SP363. <https://doi.org/10.37765/ajmc.2020.88567>
62. Chernew ME, Fendrick AM, Inzerro A. After 25 years, *AJMC*® looks to the future: a Q&A with Michael E. Chernew, PhD, and A. Mark Fendrick, MD. *Am J Manag Care*. 2020;26(12):497-498. doi: 10.37765/ajmc.2020.88536.
63. Fendrick AM. At Least Two Surprising Insights About Value-Based Care. Relentless Health Value Podcast. 2021. <https://relentlesshealthvalue.com/audios/ep308/>
64. Fendrick AM. Promoting High Value Care: A Conversation with Mark Fendrick. Choosing Wisely Newsletter. 2021. <https://www.choosingwisely.org/resources/updates-from-the-field/promoting-high-value-care-a-conversation-with-mark-fendrick/>
65. Fendrick AM. NEBGH Medical Director’s Weekly Monday COVID-19 Update. “Mondays with Dr. Mark” webinar series. <https://nebgh.org/wp-content/uploads/2021/02/020121.pdf>
66. Beaudin-Seiler B, Rhyan C, Fendrick AM, Miller G. Similarities and Differences Between States with Varying Rates of Low-Value Care: A Qualitative Review. Research Consortium for Health Care Value Assessment. 2021. https://www.hcvalueassessment.org/application/files/6616/1357/2845/Research_Consortium_Research_Brief_No._3.pdf
67. Fendrick AM. GoodRx helps people afford drugs. But is it improving health care or profiting off a broken system? *Fortune*. 2021. <https://fortune.com/2021/04/29/goodrx-prescription-drug-costs-pbms/>
68. Fendrick AM. Progressing from COVID Cost-Sharing Waivers to Less Low-Value Spending. Xtelligent Healthcare Media. <https://www.xtelligentmedia.com/podcasts/P4>
69. Fendrick AM. Value-Based Insurance Design: Enhancing Access and Affordability to Essential Clinical Services. *Outcomes Rocket*. <https://outcomesrocket.health/value-based-insurance-design-enhancing-access-and-affordability-to-essential-clinical-services/2021/06/>
70. Fendrick AM. Value-Based Insurance Design & the Digital Front Door with Dr. Mark Fendrick. *Bright Spots in Healthcare*. <https://www.stitcher.com/show/bright-spots-in-healthcare/episode/value-based-insurance-design-the-digital-front-door-with-dr-mark-fendrick-84936119>
71. Johnson KS, Giunto N, Fendrick AM. Aligning to Drive Value. Washington Health Alliance. https://wahealthalliance.org/wp-content/uploads/2021/06/Aligning_to_Drive_Value_final.pdf

Articles Accepted for Publication

1. Lowry KP, Bell S, Fendrick AM, Carlos RC. Out-of-Pocket Costs for Diagnostic Breast Imaging Services After Screening Mammography Among Commercially Insured Women from 2010-2017. *JAMA Network Open*.
2. Fisher DA, Princic N, Miller-Wilson LA, Wilson K, Fendrick AM, Limburg P. Colorectal Cancer Screening Test Utilization Among Average Risk Individuals: a Longitudinal Analysis. *JAMA Network Open*.

Articles Submitted for Publication

1. Cliff EQ, Hirth R, Fendrick AM. Incentives Intended to Increase Uptake of High-Value Preventive Care Services. *Med Care*.
2. Dalton VK, Moniz MH, Heisel E, Carlos RC, Kobernik EK, Kolenic GE, Fendrick AM. Income- Related Differences in Effective Contraception Uptake Following the Elimination of Cost Sharing Among Commercially Insured Women. *Obstet Gynecol*.

3. Yan J, Kim DD, Oesterle S, Fendrick AM. An Evidence-Based Approach to Inform Consumer Cost-Sharing for Clinical Services: Implications for Health Reform. *Value Health*.
4. Berinstein JA, Cohen-Mekelburg SA, Greenberg GM, Wray D, Berry SK, Saini SD, Fendrick AM, Adams MA, Waljee AK, Higgins PDR. A Multicomponent Care Coordination Intervention Improves Patient Symptoms Without Increasing Costs for High-Risk Patients with Inflammatory Bowel Disease: The CAPTURE IBD Trial. *American Journal of Gastroenterology*.
5. Sadigh G, Charkhchi P, Fendrick AM, Hassan DG, Hatfield A, Carlos R. Financial burden of Advanced Imaging in Radiology (FAIR Study). *JGIM*.
6. Tailor T, Bell S, Fendrick AM, Carlos R. Total and Out-of-Pocket Costs of Procedures after Lung Cancer Screening in a National Commercially Insured Population: Estimating An Episode of Care. *CHEST*.
7. Fendrick AM, Pulungan Z, Teigland C, Lautsch D, Mentz R, Hilkert R, Yang M, Djatche L. Out-of-Pocket Payments for Part D Covered Medications by Medicare Fee-for-Service Beneficiaries with Heart Failure with Reduced Ejection Fraction. *Journal of the American Heart Association*.
8. Strohbehn GW, Cooperrider JH, Yang D, Fendrick AM, Ratain MJ, Zaric GS. Scalable pay-for-performance? Pfizer and Palbociclib in China. *Journal of Clinical Oncology*.
9. Janson J, Aintabi D, Cohen Mekelburg SA, DeJonckheere M, Allen JI, Irani DN, Fendrick AM, Waljee AK, Higgins PDR, Berinstein JA. Patient Concerns and Experiences on Transition to Home-Based Infusions During the COVID-19 Pandemic. *Journal of Crohn's and Colitis*.
10. Fendrick AM, Borah BJ, Ozbay AB, Saoud L, Limburg PJ. Life-Years Gained Resulting from Screening Colonoscopy Compared With Follow-Up Colonoscopy after a Positive Stool-Based Colorectal Screening Test. *Annals of Internal Medicine*.
11. Mmonu N, Radix A, Zhao L, Makarov D, Bluebond-Langner R, Fendrick AM, Castle E, Berry C. Patient reported outcomes in genital gender-affirming surgery: the time is now. *Value in Health*.
12. Fendrick AM, Rhyan C, Beaudin-Seiler B, Tale A, Miller G. Price Growth of Medicare Services After Elimination of Consumer Cost-Sharing. *Health Affairs*.
13. Mmonu N, Radix A, Fendrick AM. Determining the Benefits of Gender-affirming Surgery: A Call for Action. *JAMA Surgery*.
14. Fendrick AM, Dalton VK, Tilea A, Malone A, Moniz MH. Out-of-Pocket Costs for Colposcopy Among Commercially Insured Women from 2006-2019. *Obstetrics & Gynecology*.
15. Scott JW, Fendrick AM. The Hazards of Cost Sharing for Emergency Surgical Conditions: Moral, Clinical, and Financial. *JAMA Health Forum*.
16. Kim DD, Griauzde D, Richardson C, Fendrick AM. Clinically-Driven Payment and Benefit Design to Improve Health Equity: The Case of Obesity Prevention and Treatment. *Annals of Internal Medicine*.
17. Fendrick AM, Princic N, Miller-Wilson L, Wilson K, Limburg P. Out-of-Pocket Costs for Subsequent Colonoscopy After Non-Invasive Colorectal Cancer Screening Test Among Commercially Insured and Medicare Beneficiaries. *American Journal of Gastroenterology*.

Proceedings

1. Fendrick AM, Goodman CS, Schwartz JS. The Program on Outcomes Research in Technology. *Journal of Laparoendoscopic Surgery*. 1993;3: 263-67.
2. Fendrick AM. The Need for Outcomes Research in Evaluating the Benefit of Health Care Technology, in *Health Care Technology Policy I: The Role of Technology in the Cost of Health Care*, Warren S. Grundfest, Editor, Proc. SPIE 2307, 125-133 (1994).

3. Fendrick AM. Outcomes Research in Evaluating the Benefit of Health Care Technology, in Health Care Technology Policy II: The Role of Technology in the Cost of Health Care, Warren S. Grundfest, Editor, Proc. SPIE 2449, 68-73 (1995).
4. Fendrick AM. Managing Peptic Ulcer Disease in the Era of Helicobacter pylori, in Paradigm: A Practical Guide, Mary Alderman, Editor, ISSN 1091-8396, (1996).
5. Fendrick AM. Economic Considerations in the Treatment of Reflux Disease. The Management of Acid Peptic Diseases. MPE Communications. 1999;1(2):9-10.
6. Barrardi RR, Fendrick AM. Proton Pump Inhibitors: Update on Comparative Pharmacology, Clinical Efficacy, Safety, and Use in Patients with Acid-Related Diseases. American Council on Pharmaceutical Education, Program No: 424-000-01-032-H01.
7. Saltiel E, Chey W, Fendrick AM. Optimizing Treatment Regimens for Patients at Risk for NSAID-Related Adverse Events: Addressing the Confusion Over “Cox”icity. Program No: 424- 000-02-005-H01.

Editorials

1. Fendrick AM. Towards a National Hepatitis B Vaccination Program. Hosp Pract. 1994;29:9-15.
2. Fendrick AM. Thrombolytic Therapy: Just Do It. J Gen Intern Med. 1995;10(6):351-352.
3. Tierney WM, Fendrick AM. Economic Evaluation of Alternative Adjuvant Chemotherapy Modalities for Colorectal Carcinoma. J Clin Gastroenterol. 1996;23(4):248-250.
4. Jeffries MA, Scheiman JM, Fendrick AM. Helicobacter pylori Eradication: Kill the Bug and Save the Pill? Am J Gastroenterol. 1998;93(7):1183-1184.
5. Gorelick AB, Scheiman JM, Fendrick AM. Identification of Patients with Resectable Pancreatic Cancer: At What Stage Are We? Am J Gastroenterol. 1998;93(10):1995-1996.
6. Fendrick AM, Scheiman JM. Healing and Prevention of NSAID-Associated Ulcer Disease: Is Seeing Believing? Am J Gastroenterol. 1998;93(12):2628-2629.
7. Saint S, Fendrick AM. Economic Immunity in the ICU: Continued Support or Pull the Plug? Intensive Care Med. 1999;25(4):345-347.
8. Fendrick AM. Benefit-Based Co-pays: An Alternative Approach to Formulary Management. Sem Med Pract. 2000;3(1):32.
9. Fendrick AM, Scheiman JM. Decision Analytic Modeling and NSAID Gastropathy: Could we be More Sensitive? J Gen Intern Med. 2000; 15(6):430-431.
10. Scheiman JM, Fendrick AM. NSAID’s Without a Prescription: Over-counter Access, Under-counted Risks. Am J Gastroenterol. 2002; 97(9):2159-2161.
11. Fendrick AM. Mechanisms to Improve Pharmaceutical Use in Managed Care: To Study Controls, Control the Studies [Please]. Am J Manag Care. 2003;9(11):711-712.
12. Carlos RC, Fendrick AM. Improving Cancer Screening Adherence: Using the “Teachable Moment” as a Delivery Setting for Educational Interventions. Am J Manag Care. 2004;10(4):247-248.
13. Scheiman JM, Fendrick AM. Informed Choices in Anti-Inflammatory Drug Therapy: Why Patient Risk Matters. J Clin Rheum. 2004;10(4):157-159.
14. Fendrick AM. COX-2 Inhibitor Use after Vioxx: Careful Balance or End of the Rope? Am J Manag Care. 2004;10(11 Pt 1):740-741.
15. Carlos, RC, Fendrick AM. Value Added Radiology: Using Existing Radiology Services to Improve Cancer Screening. Acad Radiol. 2005;12(4):475-478.
16. Carlos, RC, Fendrick AM. Meeting the Challenge of Colorectal Cancer Screening. Gastrointest Endosc. 2005;62(6): 884-5.
17. Fendrick AM, Chernew ME. Value Based Insurance Design. A “Clinically Sensitive” Approach to Preserve Quality and Contain Costs. Am J Manag Care. 2006;12(1):18-20.

18. Fendrick AM. The Future of Health Economic Modeling: Have We Gone Too Far or Not Far Enough? *Value Health*. 2006;9(3):179-80.
19. Fendrick AM, Chernew ME. Value Based Insurance Design: A “Clinically Sensitive, Fiscally Responsible” Approach to Mitigate the Adverse Clinical Effects of High-Deductible Consumer-Directed Health Plans. *J Gen Intern Med*. 2007;22(6):890-1.
20. Chernew M, Fendrick AM. Value and Increased Cost Sharing in the American Health Care System. *Health Serv Res*. 2008;43(2):451-7.
21. Fendrick AM, Chernew ME. Value Based Insurance Design: Maintaining a Focus on Health in an Era of Cost Containment. *Am J Manag Care*. 2009;15(6):338.
22. Dorn SD, Fendrick AM. Waiving Cost Sharing for Screening Colonoscopy – Free, But Not Clear. *Clin Gastroenterol Hepatol*. 2012;10(7):767-8.
23. Cox JV, Fendrick AM. Transformation. *J Oncol Pract*. 2012;8(3Suppl):1s.
24. Sharp A, Fendrick AM. Inside Out: Reversing the Focus on Emergency Departments to Enhance Efficiency. *Am J Manag Care*. 2013;19(1):33-35.
25. Fendrick AM. Alignment of Consumer and Provider Incentives: As Easy as Peanut Butter and Jelly. *Am J Account Care*. 2014;2(3):10.
26. Cliff EQ, Fendrick AM. Insured but Not Covered—Using Clinical Nuance to Create “Smarter Deductibles.” *Am J Account Care*. 2015;3(1):10.
27. Fendrick AM. The Impact of Value-Based Insurance Design on Oncology Drugs. *Clin Adv Hematol Oncol*. 2016;14(1):14-6.
28. Chernew ME, Fendrick AM. A New Chapter in Health Reform. *Am J Manag Care*. 2016;22(11):711.
29. Cliff EQ, Fendrick AM. “Clinically Nuanced” Medicaid Cost-Sharing. *J Med Econ*. 2018;21(2):189-191. DOI: 10.1080/13696998.2017.1388807.
30. Fendrick AM, Soonavala R. Expanding the "Safe Harbor" in High-deductible Health Plans: Better Coverage and Lower Healthcare Costs. *Am J Manag Care*. 2017;23(12):724-725.
31. Sharp A, Fendrick AM. Delivery of Acute Unscheduled Healthcare: Who Should Judge Whether a Visit is Appropriate (or Not)? *Am J Manag Care*. 2018;24(5):223-224.
32. Patel K, Fendrick AM. Insights on Site-of-Care Research: Both Quality and Cost Information Are Necessary to Guide Policy. *Am J Manag Care*. 2018;24(7):316-317.
33. Budros M, Fendrick AM. Levers to Reduce Use of Unnecessary Services: Creating Needed Headroom to Enhance Spending on Evidence-Based Care. *Am J Manag Care*. 2018;24(8):353-355.
34. Chhabra K, Dimick J, Fendrick AM. Value-Based Insurance Coverage for Bariatric Surgery: Time for Surgeons to Lead the Change. *Surg Obes Relat Dis*. 2019;15(1):152-154. DOI: 10.1016/j.soard.2018.11.012.
35. Fendrick AM, George D. The Drug Price Iceberg: More Than Meets the Eye. *Am J Manag Care*. 2019;25(2):57-58.
36. Cliff BQ, Fendrick AM. Open Doors to Primary Care Should Add a “Screen” to Reduce Low-Value Care. *Am J Manag Care*. 2019;25(5):216-217.
37. Fendrick AM, Buxbaum JD. Precision Medicines Needs Precision Patient Assistance Programs. *Am J Manag Care*. 2019;25(7):294-295.
38. Fendrick AM. Expand Predeductible Coverage Without Increasing Premiums or Deductibles. *Am J Manag Care*. 2020;26(2):61-62.
39. Fendrick AM, Shrosbree B. Expanding coverage for essential care during COVID-19. *Am J Manag Care*. 2020;26(5):195-196. DOI: 10.37765/ajmc.2020.42920
40. Hadeed N, Fendrick AM. Enhance Care Continuity Post COVID-19. *Am J Manag Care*. 2021;27(4):135-136. <https://doi.org/10.37765/ajmc.2021.88508>

41. Che Z, Fendrick AM, Tapper, EB. Baffled by NAFLD: The Horse Might Be Out of the Barn, but Should Not Take Us For a Ride. *Am J Manag Care*. 2021;27(9):In Press.
<https://www.ajmc.com/view/baffled-by-nafl-d-the-horse-might-be-out-of-the-barn-but-should-not-take-us-for-a-ride>

Chapters in Books

1. Hillman AL, Fendrick AM. The Technological Imperative. In: Nash DB, ed. *Future Practice Alternatives in Medicine*. Second Edition. New York: Igaku-Shoin. 1993.
2. Fendrick AM, Schwartz JS. Physicians' Decisions Regarding the Acquisition of Technology. In: Gelijns AC and Dawkins HV, eds. *Medical Innovations at the Crossroads*. Vol. 4, Adopting New Medical Technology. Washington D.C.: National Academy Press. 1994;71-84.
3. Fendrick AM. Assessing New Treatments - Biliary Stone Disease. In: Szczepura A and Kankaanpää J, eds. *Assessment of Health Care Technologies: Case Studies, Key Concepts and Strategic Issues*. New York: John Wiley. 1996;105-122.
4. Chey WD, Fendrick AM. Noninvasive Helicobacter pylori Diagnostic Tests-Recent Innovations. *Harrison's OnLine*. World Wide Web. McGraw-Hill. 1999. DOI: 10.1036/1096-7133.ch284.
5. Fendrick AM. Clinical and Economic Effects of Nonprescription Therapy in the Treatment of Dyspepsia. In: Johnson DA, Katz PO, and Castell DO, eds. *Dyspepsia*. Philadelphia: American College of Physicians. 2001;199-134.
6. Inadomi JM, Fendrick AM. Dyspepsia. Physicians Information and Education Resource. <http://pier.acponline.org/physicians/diseases/d169> [Date accessed: 2003 Jan 18] In: PIER. Philadelphia: American College of Physicians-American Society of Internal Medicine. 2003.
7. Fendrick AM. A Patient at Risk of a Serious Gastrointestinal Events Related to Anti-Inflammatory Therapy. In: *Case-Based Medicine Teaching Series: Acid Related Disorders*. New York: McMahon Publishing Group. 2004;86-94.
Chernew ME, Fendrick AM, Glied SA, Ignagni K, Parente ST, Robinson JC, Wilensky GR. Benefit Design to Promote Effective, Efficient, and Affordable Care. In: *Vital Directions for Health & Health Care: An Initiative of the National Academy of Medicine*. Washington, DC: National Academy of Medicine. 2016;175-190. DOI: 10.31478/201609h.
8. Fendrick AM, Oesterle SL, Shope M, Hatzigeorgiou M. Value-Based Insurance Design. In: *The Healthcare Quality Book: Vision, Strategy, and Tools*. Chicago, IL: Health Administration Press. 2019;415-438.

Letters

1. Edelson JT, Bohrer MS, Fendrick AM, Gonzales JJ, Morrison MF, Uffner J. Premenstrual Syndrome (letter). *NEJM*. 1985;312:920.
2. Gonzales JJ, Edelson JT, Bohrer MS, Fendrick AM, Morrison MF. Proteinuria and Oral Gold Treatment (letter). *Ann Intern Med*. 1985;102:561.
3. Fendrick AM. Cost-Effectiveness of Symptomatic Gallstone Management: What Exactly Are We Measuring? (letter). *Gastroenterol*. 1992;102:745-6.
4. Bloom BS, Hillman AL, Fendrick AM, Schwartz JS. Cost and Effectiveness of Hepatitis B Vaccination (letter). *Ann Intern Med*. 1993;119:536-7.
5. Tierney WM, Fendrick AM. Cost-Effectiveness Model of Colorectal Cancer Screening (letter). *Gastroenterol*. 1996;110(6):2026-2027.
6. Nallamotheu BK, Saint S, Rubenfire M, Fendrick AM. Electron Beam Computed Tomography in the Diagnosis of Obstructive Coronary Artery Disease (letter). *J Am Coll Cardiol*. 2001;37(2):689-690.
7. Nallamotheu BK, Saint S, Rubenfire M, Fendrick AM. Electron-Beam Computed Tomography as a Population Screening Tool (letter). *Arch Intern Med*. 2001;161(1):2624-2625.

8. Fendrick AM, Smith DG, Chernew ME, Shaw SN. A Benefit Based Copay for Prescription Drugs: Patient Contribution Based on Total Benefits, Not Drug Acquisition Cost (letter). *Am J Manag Care*. 2002;8(2):128-130.
9. Blitz, SG, Chapman, DK, Fendrick, AM. The Role of Physical Therapy in Occupational Low Back Injuries (letter). *J Occup Environ Med*. 2002;44(6):489-490.
10. Fendrick AM. Health Investment Costs and Benefits (letter). *Health Aff*. 2002;21(5):300-301.
11. Cram P, Fendrick AM, Vijan S. Public Use of Automated External Defibrillators (letter). *NEJM*. 2003;348(8):755-6.
12. Rosen AB, Fendrick AM, Vijan S. Medicare Coverage of Angiotensin-Converting Enzyme Inhibitors (letter). *Ann Intern Med*. 2005;143(2):89-99.
13. Earnshaw SR, Scheiman J, Fendrick AM, McDade C, Pignone M. Cost-Utility of Aspirin and Proton Pump Inhibitors for Primary Prevention. *Arch Intern Med*. 2011;171(3):218-25.
14. Buxbaum JD, Cohen AJ, Fendrick AM. Measures of the Burden of Medical Expenses. *JAMA*. 2018;319(15):1621. DOI:10.1001/jama.2018.1315.
15. Shrosbree B, Fendrick AM. Assessing the Effectiveness of V-BID Implementations. *J Manag Care Spec Pharm*. 2019;25(9):1026-1027. DOI: 10.18553/jmcp.2019.25.9.1026.